: The AMEDEO Literature Guide

Home The Word Brain

My Amedeo

FAQ

Privacy

About

Flying Publisher

COVID-19: Daily Top 10 Papers

Leukemia

Free Subscription

Articles published in Br J Haematol
Retrieve available abstracts of 498 articles:
HTML format

Single Articles

June 2021

OSTERGAARD J, Jonart LM, Ebadi M, Koppenhafer SL, et al
Preclinical efficacy of prexasertib in acute lymphoblastic leukemia.
Br J Haematol. 2021 Jun 7. doi: 10.1111/bjh.17610.
PubMed

February 2021

WOUTERS Y, Nevejan L, Louwagie A, Devos H, et al
Efficacy of ruxolitinib in B-lymphoblastic leukaemia with the PCM1-JAK2 fusion gene.
Br J Haematol. 2021;192:e112-e115.
PubMed

WANG J
Leukaemia blues - an unusual presentation of leukaemia cutis.
Br J Haematol. 2021;192:676.
PubMed

GORDON MJ, Huang J, Chan RJ, Bhargava P, et al
Medical comorbidities in patients with chronic lymphocytic leukaemia treated with idelalisib: analysis of two large randomised clinical trials.
Br J Haematol. 2021;192:720-728.
PubMed Abstract available

EGHOLM GJ, Andersen MA, Andersen CL, Frederiksen H, et al
Abnormal eosinophil count at CLL diagnosis correlates with shorter treatment free survival.
Br J Haematol. 2021;192:e81-e84.
PubMed

HOTINSKI AK, Best OG, Thurgood LA, Lower KM, et al
A biclonal case of chronic lymphocytic leukaemia with discordant mutational status of the immunoglobulin heavy chain variable region and bimodal CD49d expression.
Br J Haematol. 2021;192:e77-e81.
PubMed

ALI AM, Cooper J, Walker A, Jones D, et al
Adult-onset acute myeloid leukaemia in a patient with germline mutation of CBL.
Br J Haematol. 2021;192:665-667.
PubMed

BRAUNSTEIN Z, Mishra A, Staub A, Freud AG, et al
Clinical outcomes in T-cell large granular lymphocytic leukaemia: prognostic factors and treatment response.
Br J Haematol. 2021;192:484-493.
PubMed Abstract available

FLOETH M, Elges S, Gerss J, Schwoppe C, et al
Low-density lipoprotein receptor (LDLR) is an independent adverse prognostic factor in acute myeloid leukaemia.
Br J Haematol. 2021;192:494-503.
PubMed Abstract available

MORENO BERGGREN D, Kjellander M, Backlund E, Engvall M, et al
Prognostic scoring systems and comorbidities in chronic myelomonocytic leukaemia: a nationwide population-based study.
Br J Haematol. 2021;192:474-483.
PubMed Abstract available

DIAMANTI P, Ede BC, Dace PE, Barendt WJ, et al
Investigating the response of paediatric leukaemia-propagating cells to BCL-2 inhibitors.
Br J Haematol. 2021;192:577-588.
PubMed Abstract available

January 2021

AKINOSOGLOU K, Paliogianni F, Spyridonidis A, Symeonidis A, et al
SARS-CoV-2 persistence and non-protective immunity in infected haematological patients.
Br J Haematol. 2021;192:e51-e54.
PubMed

BRECCIA M
Autologous stem cell transplantation finds a place in acute promyelocytic leukaemia.
Br J Haematol. 2021;192:237-238.
PubMed

ROSS DM, Hughes TP
Counterpoint: There is a best duration of deep molecular response for treatment-free remission, but it is patient-specific, and that is the challenge.
Br J Haematol. 2021;192:24-27.
PubMed Abstract available

KARAGIANNIS P, Alsdorf W, Tallarek AC, Blohm ME, et al
Treatment of refractory acute myeloid leukaemia during pregnancy with venetoclax, high-dose cytarabine and mitoxantrone.
Br J Haematol. 2021;192:e60-e63.
PubMed

FOUZIA NA, Sharma V, Ganesan S, Palani HK, et al
Management of relapse in acute promyelocytic leukaemia treated with up-front arsenic trioxide-based regimens.
Br J Haematol. 2021;192:292-299.
PubMed Abstract available

JIN W, Chen L, Liu Y, Chen Q, et al
A novel KMT2A-USO1 fusion gene-induced de novo secondary acute myeloid leukaemia in a patient initially diagnosed with acute promyelocytic leukaemia.
Br J Haematol. 2021;192:e32-e36.
PubMed

OTTAVIANO G, Baird S, Bonney D, Connor P, et al
The role of immunotherapy in relapse/refractory precursor-B acute lymphoblastic leukaemia: real-life UK/Ireland experience in children and young adults.
Br J Haematol. 2021;192:e42-e44.
PubMed

CAVALLINI C, Galasso M, Pozza ED, Chignola R, et al
Effects of CD20 antibodies and kinase inhibitors on B-cell receptor signalling and survival of chronic lymphocytic leukaemia cells.
Br J Haematol. 2021;192:333-342.
PubMed Abstract available

GALE RP, Saglio G
Point: Is there a best duration of deep molecular response to achieve therapy-free remission in chronic myeloid leukaemia?
Br J Haematol. 2021;192:22-23.
PubMed

MATSUO H, Wakita T, Hiramatsu H, Ohmori K, et al
Blast cells in acute megakaryoblastic leukaemia with Down syndrome are characterized by low CLEC12A expression.
Br J Haematol. 2021;192:e7-e11.
PubMed

MASON CC, Fiol CR, Baker MJ, Nadal-Melsio E, et al
Identification of genetic targets in acute myeloid leukaemia for designing targeted therapy.
Br J Haematol. 2021;192:137-145.
PubMed Abstract available

FRISANCO OLIVEIRA A, Tansini A, Toledo TR, Balceiro R, et al
Immunophenotypic characteristics of juvenile myelomonocytic leukaemia and their relation with the molecular subgroups of the disease.
Br J Haematol. 2021;192:129-136.
PubMed Abstract available

RADICH J
Molecular testing of chronic myeloid leukaemia in low resource areas.
Br J Haematol. 2021;192:28-32.
PubMed Abstract available

DUAN W, Liu X, Jia J, Wang J, et al
The loss or absence of minimal residual disease of <0.1% at any time after two cycles of consolidation chemotherapy in CBFB-MYH11-positive acute myeloid leukaemia indicates poor prognosis.
Br J Haematol. 2021;192:265-271.
PubMed Abstract available

MILOJKOVIC D, Cross NCP, Ali S, Byrne J, et al
Real-world tyrosine kinase inhibitor treatment pathways, monitoring patterns and responses in patients with chronic myeloid leukaemia in the United Kingdom: the UK TARGET CML study.
Br J Haematol. 2021;192:62-74.
PubMed Abstract available

December 2020

NAKAHATA S, Morishita K
Commentary on: clinical significance of CD28 gene-related activating alterations in adult T-cell leukaemia/lymphoma.
Br J Haematol. 2020 Dec 14. doi: 10.1111/bjh.17214.
PubMed

NELSON ND, McMahon CM, El-Sharkawy Navarro F, Freyer CW, et al
Rapid fluorescence in situ hybridisation optimises induction therapy for acute myeloid leukaemia.
Br J Haematol. 2020;191:935-938.
PubMed

CHEN J, Wang F, Fang J, Nie D, et al
Dynamic evolution of ponatinib-resistant mutations in BCR-ABL1-positive leukaemias revealed by next-generation sequencing.
Br J Haematol. 2020;191:e113-e116.
PubMed

PARRY-JONES N, Joshi A, Forconi F, Dearden C, et al
Guideline for diagnosis and management of hairy cell leukaemia (HCL) and hairy cell variant (HCL-V).
Br J Haematol. 2020;191:730-737.
PubMed

GANGAT N, Morsia E, Foran JM, Palmer JM, et al
Venetoclax plus hypomethylating agent in blast-phase myeloproliferative neoplasm: preliminary experience with 12 patients.
Br J Haematol. 2020;191:e120-e124.
PubMed

MOORMAN AV, Schwab C, Winterman E, Hancock J, et al
Adjuvant tyrosine kinase inhibitor therapy improves outcome for children and adolescents with acute lymphoblastic leukaemia who have an ABL-class fusion.
Br J Haematol. 2020;191:844-851.
PubMed Abstract available

MERYK A, Kropshofer G, Hutter J, Fritz J, et al
Benefits of risk-adapted and mould-specific antifungal prophylaxis in childhood leukaemia.
Br J Haematol. 2020;191:816-824.
PubMed Abstract available

SIBAI H, Chen R, Liu X, Falcone U, et al
Anticoagulation prophylaxis reduces venous thromboembolism rate in adult acute lymphoblastic leukaemia treated with asparaginase-based therapy.
Br J Haematol. 2020;191:748-754.
PubMed Abstract available

FRISCH A, Rowe JM, Ofran Y
How we treat older patients with acute myeloid leukaemia.
Br J Haematol. 2020;191:682-691.
PubMed Abstract available

November 2020

ZHANG X, Suo S, Wang J, Jin J, et al
IDH1(R132S) -mutated acute lymphoblastic leukaemia resembles Burkitt lymphoma/leukaemia via activating MYC.
Br J Haematol. 2020 Nov 21. doi: 10.1111/bjh.17199.
PubMed

SAKAMOTO Y, Ishida T, Masaki A, Takeshita M, et al
Clinical significance of CD28 gene-related activating alterations in adult T-cell leukaemia/lymphoma.
Br J Haematol. 2020 Nov 18. doi: 10.1111/bjh.17211.
PubMed Abstract available

MONDELLO P, Zelenetz AD
Reshaping the therapeutic landscape of chronic lymphocytic leukaemia in the era of targeted therapy.
Br J Haematol. 2020;191:326-328.
PubMed

CHAGALUKA G, Schwalbe EC, Chakumatha E, Carey P, et al
Challenges of starting treatment protocols for acute lymphoblastic leukaemia in a low-income setting - the Blantyre experience.
Br J Haematol. 2020;191:e87-e90.
PubMed

CASSADAY RD, Marks DI, DeAngelo DJ, Jabbour EJ, et al
Impact of number of cycles on outcomes of patients with relapsed or refractory acute lymphoblastic leukaemia treated with inotuzumab ozogamicin.
Br J Haematol. 2020;191:e77-e81.
PubMed

TUEUR G, Lazarian G, Eclache V, Fleury C, et al
Prevalence, distribution and predictive value of XPO1 mutation in a real-life chronic lymphocytic leukaemia cohort.
Br J Haematol. 2020;191:e90-e94.
PubMed

MATTSSON A, Sylvan SE, Asklid A, Wiggh J, et al
Risk-adapted bendamustine + rituximab is a tolerable treatment alternative for elderly patients with chronic lymphocytic leukaemia: a regional real-world report on 141 consecutive Swedish patients.
Br J Haematol. 2020;191:426-432.
PubMed Abstract available

DERRIEUX C, Gish A, Caulier A, Grardel N, et al
Shared clonal IGH rearrangement in BCP-ALL occurring after CLL: pitfalls and implications for MRD monitoring.
Br J Haematol. 2020;191:506-509.
PubMed

IRANI YD, Hughes A, Clarson J, Kok CH, et al
Successful treatment-free remission in chronic myeloid leukaemia and its association with reduced immune suppressors and increased natural killer cells.
Br J Haematol. 2020;191:433-441.
PubMed Abstract available

October 2020

HERISHANU Y, Levi S, Kamdjou T, Bornstein Y, et al
Obinutuzumab in the treatment of autoimmune haemolytic anaemia and immune thrombocytopenia in patients with chronic lymphocytic leukaemia/small lymphocytic lymphoma.
Br J Haematol. 2020 Oct 23. doi: 10.1111/bjh.17105.
PubMed

FOX TA, Troy-Barnes E, Kirkwood AA, Chan WY, et al
Clinical outcomes and risk factors for severe COVID-19 in patients with haematological disorders receiving chemo- or immunotherapy.
Br J Haematol. 2020;191:194-206.
PubMed Abstract available

CLARK RE
Another set of guidelines for chronic myeloid leukaemia.
Br J Haematol. 2020;191:147-149.
PubMed

GILLEECE MH, Savani BN
A stitch in time saves nine... MRD-based pre-emptive therapy.
Br J Haematol. 2020;191:19-20.
PubMed

BO A, Raiola AM, Gualandi F, Orengo G, et al
Unintentional human leukocyte antigen-mismatched haematopoietic cell transplant: clinical course and root cause analysis.
Br J Haematol. 2020;191:e35-e37.
PubMed

MONTORO J, Chorao P, Quintero A, Roca J, et al
Male genital GvHD: a hidden complication following haematopoietic stem cell transplantation.
Br J Haematol. 2020;191:12.
PubMed

SMITH G, Apperley J, Milojkovic D, Cross NCP, et al
A British Society for Haematology Guideline on the diagnosis and management of chronic myeloid leukaemia.
Br J Haematol. 2020;191:171-193.
PubMed

MCCLURE BJ, Heatley SL, Rehn J, Breen J, et al
High-risk B-cell acute lymphoblastic leukaemia presenting with hypereosinophilia and acquiring a novel PAX5 fusion on relapse.
Br J Haematol. 2020;191:301-304.
PubMed

RASHIDI A, Kaiser T, Ebadi M, Holtan SG, et al
Circulating bacterial DNA and neutropenic fever during anti-leukaemia chemotherapy.
Br J Haematol. 2020;191:e55-e58.
PubMed

DONG S, Khedro T, Ward P, Dubeau L, et al
First reported case of BRAF V600E mutation in T-cell prolymphocytic leukaemia.
Br J Haematol. 2020;191:e52-e55.
PubMed

KONG D, Qu C, Dai H, Li Z, et al
CAR-T therapy bridging to allogeneic HSCT provides durable molecular remission of Ph(+) mixed phenotype acute leukaemia with minimal residual disease.
Br J Haematol. 2020;191:e47-e49.
PubMed

KHALIFE R, Montroy J, Grigor EJM, Fergusson DA, et al
Building Canadian capacity for CAR-T cells in relapsed/refractory acute lymphoblastic leukaemia: a retrospective cohort study.
Br J Haematol. 2020;191:e14-e19.
PubMed

PAUL S, Jammal N, Akhave N, Aung PP, et al
Atypical cases of necrotizing sweet syndrome in patients with myelodysplastic syndrome and acute myeloid leukaemia.
Br J Haematol. 2020;191:e10-e13.
PubMed

CERRANO M, Castella B, Lia G, Olivi M, et al
Immunomodulatory and clinical effects of daratumumab in T-cell acute lymphoblastic leukaemia.
Br J Haematol. 2020;191:e28-e32.
PubMed

RYLAND GL, Barraclough A, Fong CY, Fleming S, et al
Inotuzumab ozogamicin resistance associated with a novel CD22 truncating mutation in a case of B-acute lymphoblastic leukaemia.
Br J Haematol. 2020;191:123-126.
PubMed

ZABKIEWICZ J, Lazenby M, Edwards G, Bygrave CA, et al
Combination of a mitogen-activated protein kinase inhibitor with the tyrosine kinase inhibitor pacritinib combats cell adhesion-based residual disease and prevents re-expansion of FLT3-ITD acute myeloid leukaemia.
Br J Haematol. 2020;191:231-242.
PubMed Abstract available

WANG J, Mou N, Yang Z, Li Q, et al
Efficacy and safety of humanized anti-CD19-CAR-T therapy following intensive lymphodepleting chemotherapy for refractory/relapsed B acute lymphoblastic leukaemia.
Br J Haematol. 2020;191:212-222.
PubMed Abstract available

GANZEL C, Wang XV, Rowe JM, Richards SM, et al
At three years, patients with acute lymphoblastic leukaemia are still at risk for relapse. Results of the international MRC UKALLXII/ECOG E2993 trial.
Br J Haematol. 2020;191:37-43.
PubMed Abstract available

September 2020

ORF K, Rogosic S, Dexter D, Ancliff P, et al
Remdesivir during induction chemotherapy for newly diagnosed paediatric acute lymphoblastic leukaemia with concomitant SARS-CoV-2 infection.
Br J Haematol. 2020;190:e274-e276.
PubMed

SILLA L
Double-bright (CD56bright/CD16bright) natural killer cell adoptive immunotherapy for SARS-CoV-2.
Br J Haematol. 2020;190:e322-e323.
PubMed

NESR G, Koshy R, Foldes D, Kagdi H, et al
Autoimmune haemolytic anaemia and a marked rise in the lymphocyte count associated with COVID-19 in a patient with treatment-naive chronic lymphocytic leukaemia: a case report.
Br J Haematol. 2020;190:e326-e328.
PubMed

SMOLEJ L
Incidence and prognostic significance of serum immunoglobulins and paraproteins in patients with chronic lymphocytic leukaemia: another valuable piece of the puzzle.
Br J Haematol. 2020;190:815-816.
PubMed

EYRE TA
Prognostication in Richter syndrome: context is everything.
Br J Haematol. 2020;190:811-812.
PubMed

CORBINGI A, Innocenti I, Tomasso A, Pasquale R, et al
Monoclonal gammopathy and serum immunoglobulin levels as prognostic factors in chronic lymphocytic leukaemia.
Br J Haematol. 2020;190:901-908.
PubMed Abstract available

SHOUMARIYEH K, Hussung S, Niemoller C, Bleul S, et al
Blastic transformation of BCR-ABL1 positive chronic myeloid leukaemia through acquisition of CBFB-MYH11 and mutant KIT.
Br J Haematol. 2020;190:e339-e343.
PubMed

DE PROPRIS MS, Intoppa S, Milani ML, Mariglia P, et al
ROR1 is an accurate and reliable marker of minimal residual disease in chronic lymphocytic leukaemia.
Br J Haematol. 2020;190:e346-e349.
PubMed

SAITO Y, Makita S, Chinen S, Kito M, et al
Acute megakaryoblastic leukaemia with t(1;22)(p13.3;q13.1)/RBM15-MKL1 in an adult patient following a non-mediastinal germ cell tumour.
Br J Haematol. 2020;190:e329-e332.
PubMed

BRECCIA M, Vignetti M, Annibali O, Cottone F, et al
Younger age at diagnosis of acute promyelocytic leukaemia is associated with better long-term cognitive functioning.
Br J Haematol. 2020;190:e304-e307.
PubMed

FOX LC, Tan M, Brown AL, Arts P, et al
A synonymous GATA2 variant underlying familial myeloid malignancy with striking intrafamilial phenotypic variability.
Br J Haematol. 2020;190:e297-e301.
PubMed

YAMANE T, Kawakami T, Sekiguchi N, Kobayashi J, et al
High frequency of STAT3 gene mutations in T-cell receptor (TCR)gammadelta-type T-cell large granular lymphocytic leukaemia: implications for molecular diagnostics.
Br J Haematol. 2020;190:e301-e304.
PubMed

HANEKAMP D, Snel AN, Kelder A, Scholten WJ, et al
Applicability and reproducibility of acute myeloid leukaemia stem cell assessment in a multi-centre setting.
Br J Haematol. 2020;190:891-900.
PubMed Abstract available

OFFNER F, Robak T, Janssens A, Govind Babu K, et al
A five-year follow-up of untreated patients with chronic lymphocytic leukaemia treated with ofatumumab and chlorambucil: final analysis of the Complement 1 phase 3 trial.
Br J Haematol. 2020;190:736-740.
PubMed Abstract available

TURKINA A, Wang J, Mathews V, Saydam G, et al
TARGET: a survey of real-world management of chronic myeloid leukaemia across 33 countries.
Br J Haematol. 2020;190:869-876.
PubMed Abstract available

VARGHESE AM, Sood N, Daniel SM
Current pricing model for cancer drugs - is it 'Justum Pretium' for the developing world? Taking management of chronic lymphocytic leukaemia in India into consideration.
Br J Haematol. 2020;190:e292-e294.
PubMed

EL CHAER F, Ballen KK
Treatment of acute leukaemia in adult Jehovah's Witnesses.
Br J Haematol. 2020;190:696-707.
PubMed Abstract available

August 2020

RANGER A, Haji R, Kaczmarski R, Danga A, et al
Interleukin-6 blockade treatment for COVID-19 associated cytokine release syndrome in a patient with poorly controlled chronic myeloid leukaemia.
Br J Haematol. 2020;190:e128-e130.
PubMed

PICIOCCHI A, Messina M, Soddu S, La Sala E, et al
The COVID-19 pandemic and management of GIMEMA clinical trials: changes and challenges.
Br J Haematol. 2020;190:e211-e214.
PubMed

FARAH N, Burt R, Ibrahim AR, Baker R, et al
Concerns about how to use established minimal residual disease monitoring in the treatment of NPM1-mutant acute myeloid leukaemia (AML) following reduced intensity chemotherapy protocols for AML given as a result of the COVID-19 pandemic.
Br J Haematol. 2020;190:e208-e210.
PubMed

CHOPRA J, Hiew HJ, Cumpstey A, Cagampang F, et al
Successful treatment of chronic myelomonocytic leukaemia with hydroxycarbamide in a patient presenting with acute hypoxic respiratory failure due to COVID-19 pneumonia.
Br J Haematol. 2020;190:e195-e198.
PubMed

INNES AJ, Cook LB, Marks S, Bataillard E, et al
Ruxolitinib for tocilizumab-refractory severe COVID-19 infection.
Br J Haematol. 2020;190:e198-e200.
PubMed

WILSON AJ, Troy-Barnes E, Subhan M, Clark F, et al
Successful remission induction therapy with gilteritinib in a patient with de novo FLT3-mutated acute myeloid leukaemia and severe COVID-19.
Br J Haematol. 2020;190:e189-e191.
PubMed

FARMER I, Okikiolu J, Steel M, Wanniarachchi C, et al
Acute promyelocytic leukaemia lying under the mask of COVID-19-a diagnostic and therapeutic conundrum.
Br J Haematol. 2020;190:e248-e250.
PubMed

LEISCH M, Greil R, Pleyer L
IDO in MDS/AML disease progression and its role in resistance to azacitidine: a potential new drug target?
Br J Haematol. 2020;190:314-317.
PubMed

ANDREWS C, Maze D, Murphy T, Sibai H, et al
Combination treatment with CPX-351 and midostaurin in patients with secondary acute myeloid leukaemia that are FLT3 mutated: three cases and review of literature.
Br J Haematol. 2020;190:467-470.
PubMed

ZHU J, Raimbault A, Sourdeau E, Maillon A, et al
Holding on to the Matutes score while dropping FMC7: new opportunity from standardised approaches in multiparameter flow cytometry.
Br J Haematol. 2020;190:e255-e258.
PubMed

GLAVEY SV, Flanagan L, Bleach R, Kelly C, et al
Secondary plasma cell leukaemia treated with single agent venetoclax.
Br J Haematol. 2020;190:e242-e245.
PubMed

CHOWDHURY A, Loaiza S, Yebra-Fernandez E, Nadal-Melsio E, et al
An ex vivo investigation of interactions between primary acute myeloid leukaemia and mesenchymal stromal cells yields novel therapeutic targets.
Br J Haematol. 2020;190:e236-e239.
PubMed

FIEDLER W, Chromik J, Amberg S, Kebenko M, et al
A Phase II study of selinexor plus cytarabine and idarubicin in patients with relapsed/refractory acute myeloid leukaemia.
Br J Haematol. 2020;190:e169-e173.
PubMed

NIE D, Zhang J, Xiong M, Wang F, et al
Complete remission of refractory juvenile acute myeloid leukaemia with RUNX1-PRDM16 in Bloom syndrome after haematopoietic stem cell transplantation.
Br J Haematol. 2020;190:e166-e169.
PubMed

PETERLIN P, Cluzeau T, Jullien M, Ngo Nloga AM, et al
Azacitidine in patients older than 80 years with acute myeloid leukaemia or myelodysplastic syndromes: a report on 115 patients.
Br J Haematol. 2020;190:461-464.
PubMed

LOKE J, Lowe DM, Miller LJ, Morton S, et al
Supportive care in the management of patients with acute myeloid leukaemia: where are the research needs?
Br J Haematol. 2020;190:311-313.
PubMed

LEBLANC FR, Pearson JM, Tan SF, Cheon H, et al
Sphingosine kinase-2 is overexpressed in large granular lymphocyte leukaemia and promotes survival through Mcl-1.
Br J Haematol. 2020;190:405-417.
PubMed Abstract available

WANG J, Lu R, Wu Y, Jia J, et al
Detection of measurable residual disease may better predict outcomes than mutations based on next-generation sequencing in acute myeloid leukaemia with biallelic mutations of CEBPA.
Br J Haematol. 2020;190:533-544.
PubMed Abstract available

WILHELMSON AS, Porse BT
CCAAT enhancer binding protein alpha (CEBPA) biallelic acute myeloid leukaemia: cooperating lesions, molecular mechanisms and clinical relevance.
Br J Haematol. 2020;190:495-507.
PubMed Abstract available

SAGLIO G, Gale RP
Prospects for achieving treatment-free remission in chronic myeloid leukaemia.
Br J Haematol. 2020;190:318-327.
PubMed Abstract available

HERUDKOVA Z, Culen M, Folta A, Jeziskova I, et al
Clonal hierarchy of main molecular lesions in acute myeloid leukaemia.
Br J Haematol. 2020;190:562-572.
PubMed Abstract available

July 2020

GESTRICH CK, Sadri N, Sinno MG, Pateva I, et al
Reciprocal ATP5L-KMT2A gene fusion in a paediatric B lymphoblastic leukaemia/lymphoma (B-ALL) patient.
Br J Haematol. 2020 Jul 29. doi: 10.1111/bjh.17000.
PubMed

BLENNERHASSETT R, Kwan J, Coyle L, Wong K, et al
Adult B- and T-lymphoblastic lymphoma treated with a paediatric acute lymphoblastic leukaemia regimen have excellent outcomes-a short report from two Sydney centres.
Br J Haematol. 2020 Jul 28. doi: 10.1111/bjh.16998.
PubMed

BARNEA SLONIM L, Ma S, Behdad A, Chen Q, et al
Pseudo-Richter transformation of chronic lymphocytic leukaemia/small lymphocytic lymphoma following ibrutinib interruption: a diagnostic pitfall.
Br J Haematol. 2020 Jul 17. doi: 10.1111/bjh.16948.
PubMed

YANG Y, Juskevicius R
T-lymphoblastic leukaemia/lymphoma with rosettes and gland-like structures.
Br J Haematol. 2020 Jul 7. doi: 10.1111/bjh.16929.
PubMed

FOA R, Bonifacio M, Chiaretti S, Curti A, et al
Philadelphia-positive acute lymphoblastic leukaemia (ALL) in Italy during the COVID-19 pandemic: a Campus ALL study.
Br J Haematol. 2020;190:e3-e5.
PubMed

DAY JW, Fox TA, Halsey R, Carpenter B, et al
Interleukin-1 blockade with anakinra in acute leukaemia patients with severe COVID-19 pneumonia appears safe and may result in clinical improvement.
Br J Haematol. 2020;190:e80-e83.
PubMed

KRUG U, Berdel WE
Smoking and AML - another piece in the puzzle.
Br J Haematol. 2020;190:143.
PubMed

MALAGOLA M, Bernardi S, Polverelli N, Russo D, et al
Minimal residual disease monitoring in acute myeloid leukaemia: are we ready to move from bone marrow to peripheral blood?
Br J Haematol. 2020;190:135-136.
PubMed

BARON F, Savani BN
Graft-versus-host-disease does not help acute lymphoblastic leukaemia patients with measurable residual disease.
Br J Haematol. 2020;190:22-23.
PubMed

ARMAND P, Murawski N, Molin D, Zain J, et al
Pembrolizumab in relapsed or refractory Richter syndrome.
Br J Haematol. 2020;190:e117-e120.
PubMed

CALVO C, Cabannes-Hamy A, Adjaoud D, Bruno B, et al
Inotuzumab ozogamicin compassionate use for French paediatric patients with relapsed or refractory CD22-positive B-cell acute lymphoblastic leukaemia.
Br J Haematol. 2020;190:e53-e56.
PubMed

KAUR U, Gambhir IS, Khare VR, Singh A, et al
Delayed resistance to imatinib after 16 years of therapy in a patient with chronic myeloid leukaemia.
Br J Haematol. 2020;190:e51-e53.
PubMed

KRISTENSEN D, Nielsen LB, Roug AS, Kristensen TC, et al
The prognostic effect of smoking status on intensively treated acute myeloid leukaemia - A Danish nationwide cohort study.
Br J Haematol. 2020;190:236-243.
PubMed Abstract available

REA B, Bailey NG
Acute myeloid leukaemia with t(8;16)(p11.2;p13.3) and erythrophagocytosis.
Br J Haematol. 2020;190:133.
PubMed

JUUL-DAM KL, Ommen HB, Nyvold CG, Walter C, et al
Measurable residual disease assessment by qPCR in peripheral blood is an informative tool for disease surveillance in childhood acute myeloid leukaemia.
Br J Haematol. 2020;190:198-208.
PubMed Abstract available

BENEFORTI L, Dander E, Bresolin S, Bueno C, et al
Pro-inflammatory cytokines favor the emergence of ETV6-RUNX1-positive pre-leukemic cells in a model of mesenchymal niche.
Br J Haematol. 2020;190:262-273.
PubMed Abstract available

ZHOU YL, Wu LX, Peter Gale R, Wang ZL, et al
Mutation topography and risk stratification for de novo acute myeloid leukaemia with normal cytogenetics and no nucleophosmin 1 (NPM1) mutation or Fms-like tyrosine kinase 3 internal tandem duplication (FLT3-ITD).
Br J Haematol. 2020;190:274-283.
PubMed Abstract available

ZHANG JM, Xu Y, Gale RP, Wu LX, et al
DPEP1 expression promotes proliferation and survival of leukaemia cells and correlates with relapse in adults with common B cell acute lymphoblastic leukaemia.
Br J Haematol. 2020;190:67-78.
PubMed Abstract available

June 2020

FAVRESSE J, Eucher C, Elsen M, Graux C, et al
Unexpected kinetics of anti-SARS-CoV-2 total antibodies in two patients with chronic lymphocytic leukemia.
Br J Haematol. 2020 Jun 17. doi: 10.1111/bjh.16954.
PubMed Abstract available

YANG LH, Zhao Y, Maule J, Rapisardo S, et al
T-lymphoblastic lymphoma and acute myeloid leukaemia transformed from myeloid neoplasm with eosinophilia: a divergent evolution of myeloid neoplasm with monosomy 7 but no detectable tyrosine kinase gene rearrangements designated by the WHO Classificat
Br J Haematol. 2020 Jun 11. doi: 10.1111/bjh.16886.
PubMed

ABRISQUETA P, Delgado J, Alcoceba M, Oliveira AC, et al
Clinical outcome and prognostic factors of patients with Richter syndrome: real-world study of the Spanish Chronic Lymphocytic Leukemia Study Group (GELLC).
Br J Haematol. 2020 Jun 9. doi: 10.1111/bjh.16748.
PubMed Abstract available

LARSSON K, Mattsson M, Ebrahim F, Glimelius I, et al
High prevalence and incidence of cardiovascular disease in chronic lymphocytic leukaemia: a nationwide population-based study.
Br J Haematol. 2020 Jun 9. doi: 10.1111/bjh.16859.
PubMed

BATALLER A, Onate G, Diaz-Beya M, Guijarro F, et al
Acute myeloid leukemia with NPM1 mutation and favorable European LeukemiaNet category: outcome after preemptive intervention based on measurable residual disease.
Br J Haematol. 2020 Jun 8. doi: 10.1111/bjh.16857.
PubMed Abstract available

WILLAN J, King AJ, Djebbari F, Turner GDH, et al
Assessing the impact of lockdown: Fresh challenges for the care of haematology patients in the COVID-19 pandemic.
Br J Haematol. 2020;189:e224-e227.
PubMed

SIENI E, Pegoraro F, Casini T, Tondo A, et al
Favourable outcome of coronavirus disease 2019 in a 1-year-old girl with acute myeloid leukaemia and severe treatment-induced immunosuppression.
Br J Haematol. 2020;189:e222-e224.
PubMed

LANGERAK AW, Davi F, Stamatopoulos K
Immunoglobulin heavy variable somatic hyper mutation status in chronic lymphocytic leukaemia: on the threshold of a new era?
Br J Haematol. 2020;189:809-810.
PubMed

STAHL M, Tallman MS
Outcomes of allogeneic stem cell transplantation for patients with t(6:9) AML- A strong case for allogeneic stem cell transplantation in first complete remission.
Br J Haematol. 2020;189:806-808.
PubMed

RAEDLER J, Heyde S, Kolokythas M, Eichinger A, et al
Venetoclax and decitabine for relapsed paediatric myelodysplastic syndrome-related acute myeloid leukaemia with complex aberrant karyotype after second stem cell transplantation.
Br J Haematol. 2020;189:e251-e254.
PubMed

DHAMI SPS, Tirincsi A, Baev D, Krawczyk J, et al
Theranostic drug test incorporating the bone-marrow microenvironment can predict the clinical response of acute myeloid leukaemia to chemotherapy.
Br J Haematol. 2020;189:e254-e258.
PubMed

LI XY, Qian JJ, Yang M, Zhang Y, et al
An oral, chemotherapy-free regimen (dasatinib plus prednisone) as induction and consolidation for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia.
Br J Haematol. 2020;189:e231-e234.
PubMed

DE FIGUEIREDO AF, Land MGP, Ferreira GM, Mencalha A, et al
Clinical and biological correlates of the expression of select Polycomb complex genes in Brazilian children with acute promyelocytic leukaemia.
Br J Haematol. 2020;189:e245-e248.
PubMed

WU X, Zhang J, Chen Q, Zhou L, et al
Efficacy of venetoclax in combination with azacitidine followed by haploidentical transplantation in refractory acute myeloid leukaemia and mixed phenotype acute leukaemia.
Br J Haematol. 2020;189:e200-e204.
PubMed

GONG Z, Zhou T, Liu H, Tang G, et al
Genotype-phenotype correlation of unusual BCR-ABL1 transcripts in Philadelphia chromosome-positive leukaemia.
Br J Haematol. 2020;189:e207-e211.
PubMed

ZHANG J, Wang Y, Li SQ, Fang L, et al
Correction of Bcl-x splicing improves responses to imatinib in chronic myeloid leukaemia cells and mouse models.
Br J Haematol. 2020;189:1141-1150.
PubMed Abstract available

LADIKOU EE, Chevassut T, Pepper CJ, Pepper AG, et al
Dissecting the role of the CXCL12/CXCR4 axis in acute myeloid leukaemia.
Br J Haematol. 2020;189:815-825.
PubMed Abstract available

RAPONI S, Ilari C, Della Starza I, Cappelli LV, et al
Redefining the prognostic likelihood of chronic lymphocytic leukaemia patients with borderline percentage of immunoglobulin variable heavy chain region mutations.
Br J Haematol. 2020;189:853-859.
PubMed Abstract available

DIAZ-BEYA M, Labopin M, Maertens J, Alijurf M, et al
Allogeneic stem cell transplantation in AML with t(6;9)(p23;q34);DEK-NUP214 shows a favourable outcome when performed in first complete remission.
Br J Haematol. 2020;189:920-925.
PubMed Abstract available

AL-ALI HK, Griesshammer M, Foltz L, Palumbo GA, et al
Primary analysis of JUMP, a phase 3b, expanded-access study evaluating the safety and efficacy of ruxolitinib in patients with myelofibrosis, including those with low platelet counts.
Br J Haematol. 2020;189:888-903.
PubMed Abstract available

PATEL BJ, Barot SV, Kuzmanovic T, Kerr C, et al
Distinctive and common features of moderate aplastic anaemia.
Br J Haematol. 2020;189:967-975.
PubMed Abstract available

May 2020

THIBAUD S, Tremblay D, Bhalla S, Zimmerman B, et al
Protective Role of BTK Inhibitors in Patients with Chronic Lymphocytic Leukemia and COVID-19.
Br J Haematol. 2020 May 20. doi: 10.1111/bjh.16863.
PubMed Abstract available

WU Y, Lin H, Xie Q, Chen Q, et al
COVID-19 in a patient with pre-existing acute lymphoblastic leukemia.
Br J Haematol. 2020 May 7. doi: 10.1111/bjh.16799.
PubMed Abstract available

BALDACINI M, Pop R, Sattler L, Mauvieux L, et al
Concomitant hemorrhagic syndrome and recurrent extensive arterial thrombosis in a patient with COVID-19 and acute promyelocytic leukemia.
Br J Haematol. 2020 May 5. doi: 10.1111/bjh.16768.
PubMed Abstract available

ANTELO G, Mangaonkar AA, Coltro G, Buradkar A, et al
Response to erythropoiesis-stimulating agents in patients with WHO-defined myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T).
Br J Haematol. 2020;189:e104-e108.
PubMed

GU X, Saunthararajah Y
Cytoplasmic dislocation of NPM1 and PU.1 in NPM1-mutated leukaemia is obscured by paraformaldehyde fixation.
Br J Haematol. 2020;189:578-581.
PubMed

GRIBBEN JG
Do we need to analyse everything at diagnosis in chronic lymphocytic leukaemia?
Br J Haematol. 2020;189:603-604.
PubMed

RAYMOND LM, Funk T, Braziel RM, Fan G, et al
Mast cell sarcoma with concurrent mast cell leukaemia.
Br J Haematol. 2020;189:e160-e164.
PubMed

ADELAIDE J, Cervera N, Guille A, Murati A, et al
Gains of EPOR and ERG genes in adult erythroleukaemia.
Br J Haematol. 2020;189:e174-e177.
PubMed

INABA H, Cao X, Chang JY, Karol SE, et al
Incidence of hip and knee osteonecrosis and their associations with bone mineral density in children with acute lymphoblastic leukaemia.
Br J Haematol. 2020;189:e177-e181.
PubMed

GIUSTI GNN, Jotta PY, Lopes CO, Ganazza MA, et al
Test trial of spike-in immunoglobulin heavy-chain (IGH) controls for next generation sequencing quantification of minimal residual disease in acute lymphoblastic leukaemia.
Br J Haematol. 2020;189:e150-e154.
PubMed

ROBINSON SE, Harrison CN
How we manage Philadelphia-negative myeloproliferative neoplasms in pregnancy.
Br J Haematol. 2020;189:625-634.
PubMed Abstract available

PRIETO-CONDE MI, Jimenez C, Garcia-Alvarez M, Ramos F, et al
Identification of relapse-associated gene mutations by next-generation sequencing in low-risk acute myeloid leukaemia patients.
Br J Haematol. 2020;189:718-730.
PubMed Abstract available

ONECHA E, Ruiz-Heredia Y, Martinez-Cuadron D, Barragan E, et al
Improving the prediction of acute myeloid leukaemia outcomes by complementing mutational profiling with ex vivo chemosensitivity.
Br J Haematol. 2020;189:672-683.
PubMed Abstract available

UDEN T, Bertaina A, Abrahamsson J, Ansari M, et al
Outcome of children relapsing after first allogeneic haematopoietic stem cell transplantation for acute myeloid leukaemia: a retrospective I-BFM analysis of 333 children.
Br J Haematol. 2020;189:745-750.
PubMed Abstract available

MIKLOS U, Strugov V, Lewerin C, Grosicki S, et al
Five-year survival follow-up of a phase III randomised trial comparing ofatumumab versus physicians' choice for bulky fludarabine-refractory chronic lymphocytic leukaemia: a short report.
Br J Haematol. 2020;189:689-693.
PubMed Abstract available

CICIARELLO M, Curti A
Good news for acute myeloid leukaemia patients from the stroll niche?
Br J Haematol. 2020;189:597-599.
PubMed

CHEN X, Chen H
BCR-ABL1-positive acute myeloid leukaemia relapsing as acute lymphoblastic leukaemia.
Br J Haematol. 2020;189:591.
PubMed

JIANG Y, Li Y, Cheng J, Ma J, et al
Upregulation of AKR1C1 in mesenchymal stromal cells promotes the survival of acute myeloid leukaemia cells.
Br J Haematol. 2020;189:694-706.
PubMed Abstract available

ZHAO Y, Maule J, McCracken J, Li Y, et al
Acute myeloid leukaemia with maturation demonstrates persistent disease with prominent megakaryoblastic differentiation 16 days following induction chemotherapy: an intra-myeloid lineage switch mediated by chemotherapy-induced clonal selection.
Br J Haematol. 2020;189:e64-e67.
PubMed

DULUCQ S, Astrugue C, Etienne G, Mahon FX, et al
Risk of molecular recurrence after tyrosine kinase inhibitor discontinuation in chronic myeloid leukaemia patients: a systematic review of literature with a meta-analysis of studies over the last ten years.
Br J Haematol. 2020;189:452-468.
PubMed Abstract available

JORDAENS S, Cooksey L, Bonney S, Orchard L, et al
Serum profiling identifies ibrutinib as a treatment option for young adults with B-cell acute lymphoblastic leukaemia.
Br J Haematol. 2020;189:500-512.
PubMed Abstract available

DELVECCHIO VS, Sana I, Mantione ME, Vilia MG, et al
Interleukin-1 receptor-associated kinase 4 inhibitor interrupts toll-like receptor signalling and sensitizes chronic lymphocytic leukaemia cells to apoptosis.
Br J Haematol. 2020;189:475-488.
PubMed Abstract available

MARAJ A, MacEneaney O, Doyle B, Quinn J, et al
Lysozyme-induced nephropathy: a rare manifestation of chronic myelomonocytic leukaemia.
Br J Haematol. 2020;189:393.
PubMed

LINCH DC, Hills RK, Burnett AK, Gale RE, et al
The clinical impact of mutant DNMT3A R882 variant allele frequency in acute myeloid leukaemia.
Br J Haematol. 2020;189:e81-e86.
PubMed

MANOUSOPOULOU A, Wang LD
ALL the comforts of homing: lymphoblasts find cerebrospinal fluid inhospitable without meningeal cell contact.
Br J Haematol. 2020;189:395-397.
PubMed

VAN DER STRATEN L, Levin MD, Visser O, Posthuma EFM, et al
Survival continues to increase in chronic lymphocytic leukaemia: a population-based analysis among 20 468 patients diagnosed in the Netherlands between 1989 and 2016.
Br J Haematol. 2020;189:574-577.
PubMed

BASILE P, Jonart LM, Ebadi M, Johnson K, et al
The meninges enhance leukaemia survival in cerebral spinal fluid.
Br J Haematol. 2020;189:513-517.
PubMed Abstract available

KLOOS R, van der Sluis IM, Mastrobattista E, Hennink W, et al
Acute lymphoblastic leukaemia patients treated with PEGasparaginase develop antibodies to PEG and the succinate linker.
Br J Haematol. 2020;189:442-451.
PubMed Abstract available

April 2020

FUSTER JL, Molinos-Quintana A, Fuentes C, Fernandez JM, et al
Blinatumomab and inotuzumab for B cell precursor acute lymphoblastic leukaemia in children: a retrospective study from the Leukemia Working Group of the Spanish Society of Pediatric Hematology and Oncology (SEHOP).
Br J Haematol. 2020 Apr 21. doi: 10.1111/bjh.16647.
PubMed Abstract available

COGLE CR, Collins B, Turner D, Pettiford LC, et al
Safety, feasibility and preliminary efficacy of single agent combretastatin A1 diphosphate (OXi4503) in patients with relapsed or refractory acute myeloid leukemia or myelodysplastic syndromes.
Br J Haematol. 2020 Apr 1. doi: 10.1111/bjh.16629.
PubMed

DHOLARIA B, Savani BN
Allogeneic haematopoietic cell transplantation after CAR T-cell therapy: safe, effective and contentious.
Br J Haematol. 2020;189:21-23.
PubMed

BERTOLI S, Rieu JB, Recher C, Vergez F, et al
Large granular lymphocytosis during quizartinib therapy.
Br J Haematol. 2020;189:7.
PubMed

EBADI M, Beckman AK, Yohe SL, Rashidi A, et al
It's all in the film.
Br J Haematol. 2020;189:8.
PubMed

OSTERROOS A, Eriksson A, Antunovic P, Cammenga J, et al
Real-world data on treatment patterns and outcomes of hypomethylating therapy in patients with newly diagnosed acute myeloid leukaemia aged >/= 60 years.
Br J Haematol. 2020;189:e13-e16.
PubMed

GODWIN CD, Bates OM, Garling EE, Beddoe ME, et al
The Bruton's tyrosine kinase inhibitor ibrutinib abrogates bispecific antibody-mediated T-cell cytotoxicity.
Br J Haematol. 2020;189:e9-e13.
PubMed

XU X, Zeng Z, Huo L, Liu H, et al
High expression of myocyte enhancer factor 2C predicts poor prognosis for adult acute myeloid leukaemia with normal karyotype.
Br J Haematol. 2020;189:e23-e27.
PubMed

ZHANG Y, Chen H, Song Y, Tan X, et al
Chimeric antigens receptor T cell therapy as a bridge to haematopoietic stem cell transplantation for refractory/ relapsed B-cell acute lymphomalastic leukemia.
Br J Haematol. 2020;189:146-152.
PubMed Abstract available

ROESSNER PM, Hanna BS, Ozturk S, Schulz R, et al
TBET-expressing Th1 CD4(+) T cells accumulate in chronic lymphocytic leukaemia without affecting disease progression in Emicro-TCL1 mice.
Br J Haematol. 2020;189:133-145.
PubMed Abstract available

WANG Y, Liu QF, Wu DP, Xu LP, et al
Improved survival after offspring donor transplant compared with older aged-matched siblings for older leukaemia patients.
Br J Haematol. 2020;189:153-161.
PubMed Abstract available

YANG RY, Yang CX, Lang XP, Duan LJ, et al
Identification of a novel RUNX1-TACC1 fusion transcript in acute myeloid leukaemia.
Br J Haematol. 2020;189:e52-e56.
PubMed

DO YR, Kwak JY, Kim JA, Kim HJ, et al
Long-term data from a phase 3 study of radotinib versus imatinib in patients with newly diagnosed, chronic myeloid leukaemia in the chronic phase (RERISE).
Br J Haematol. 2020;189:303-312.
PubMed Abstract available

ROSSOFF J, Huynh V, Rau RE, Macy ME, et al
Experience with ponatinib in paediatric patients with leukaemia.
Br J Haematol. 2020;189:363-368.
PubMed Abstract available

AWADA H, Mahfouz RZ, Durrani J, Kishtagari A, et al
Large granular lymphocytic leukaemia after solid organ and haematopoietic stem cell transplantation.
Br J Haematol. 2020;189:318-322.
PubMed Abstract available

FRAZZI R, Bizzarri V, Albertazzi L, Cusenza VY, et al
Droplet digital PCR is a sensitive tool for the detection of TP53 deletions and point mutations in chronic lymphocytic leukaemia.
Br J Haematol. 2020;189:e49-e52.
PubMed

BANKAR A, Korula A, Kulkarni UP, Devasia AJ, et al
Resource utilization and cost effectiveness of treating acute promyelocytic leukaemia using generic arsenic trioxide.
Br J Haematol. 2020;189:269-278.
PubMed Abstract available

PIETTE C, Suciu S, Bertrand Y, Uyttebroeck A, et al
Long-term outcome evaluation of medium/high risk acute lymphoblastic leukaemia children treated with or without cranial radiotherapy in the EORTC 58832 randomized study.
Br J Haematol. 2020;189:351-362.
PubMed Abstract available

March 2020

AKAHOSHI Y, Igarashi A, Fukuda T, Uchida N, et al
Impact of graft-versus-host disease and graft-versus-leukemia effect based on minimal residual disease in Philadelphia chromosome-positive acute lymphoblastic leukemia.
Br J Haematol. 2020 Mar 2. doi: 10.1111/bjh.16540.
PubMed Abstract available

PIANIGIANI G, Betti C, Brunetti L
Response to: "Cytoplasmic dislocation of NPM1 and PU.1 in NPM1-mutated leukemia is obscured by paraformaldehyde fixation".
Br J Haematol. 2020 Mar 2. doi: 10.1111/bjh.16544.
PubMed

TOUW IP, Sanders MA
Mutant allelic burden in acute myeloid leukaemia: Why bother?
Br J Haematol. 2020;188:817-818.
PubMed

RICHARDSON AI, Skikne BS, Woodroof J
Chronic myeloid leukaemia, BCR-ABL1-positive, in accelerated phase with marked eosinophilia with eosinophil atypia.
Br J Haematol. 2020;188:599.
PubMed

RADIA DH, Green A, Oni C, Moonim M, et al
The clinical and pathological panoply of systemic mastocytosis.
Br J Haematol. 2020;188:623-640.
PubMed Abstract available

XUE YJ, Suo P, Huang XJ, Lu AD, et al
Superior survival of unmanipulated haploidentical haematopoietic stem cell transplantation compared with intensive chemotherapy as post-remission treatment for children with very high-risk philadelphia chromosome negative B-cell acute lymphoblastic le
Br J Haematol. 2020;188:757-767.
PubMed Abstract available

PALOMO L, Ibanez M, Abaigar M, Vazquez I, et al
Spanish Guidelines for the use of targeted deep sequencing in myelodysplastic syndromes and chronic myelomonocytic leukaemia.
Br J Haematol. 2020;188:605-622.
PubMed Abstract available

KNOFLER R, Lange BS, Paul F, Tiebel O, et al
Bleeding signs due to acquired von Willebrand syndrome at diagnosis of chronic myeloid leukaemia in children.
Br J Haematol. 2020;188:701-706.
PubMed Abstract available

KIM YA, Ju HY, Park HJ, Lee NY, et al
Outcomes of acute lymphoblastic leukaemia in adolescent and young adult Korean patients.
Br J Haematol. 2020;188:740-744.
PubMed Abstract available

CUCCHI DGJ, Bachas C, Klein K, Huttenhuis S, et al
TP53 mutations and relevance of expression of TP53 pathway genes in paediatric acute myeloid leukaemia.
Br J Haematol. 2020;188:736-739.
PubMed Abstract available

ZHAO C, Jia B, Wang M, Schell TD, et al
Multi-dimensional analysis identifies an immune signature predicting response to decitabine treatment in elderly patients with AML.
Br J Haematol. 2020;188:674-684.
PubMed Abstract available

CHIN-YEE B, Sadikovic B, Chin-Yee IH
Genomic data in prognostic models-what is lost in translation? The case of deletion 17p and mutant TP53 in chronic lymphocytic leukaemia.
Br J Haematol. 2020;188:652-660.
PubMed Abstract available

GIONA F, Malaspina F, Putti MC, Ladogana S, et al
Results and outcome of intermittent imatinib (ON/OFF schedule) in children and adolescents with chronic myeloid leukaemia.
Br J Haematol. 2020;188:e101-e105.
PubMed

GAUR V, Chaudhary S, Tyagi A, Agarwal S, et al
Dysregulation of miRNA expression and their prognostic significance in paediatric cytogenetically normal acute myeloid leukaemia.
Br J Haematol. 2020;188:e90-e94.
PubMed

VAN DER STRATEN L, Levin MD, Visser O, Blijlevens NMA, et al
The effectiveness of ibrutinib in chronic lymphocytic leukaemia: a nationwide, population-based study in the Netherlands.
Br J Haematol. 2020;188:e109-e112.
PubMed

GRIBBEN JG
Practical management of tumour lysis syndrome in venetoclax-treated patients with chronic lymphocytic leukaemia.
Br J Haematol. 2020;188:844-851.
PubMed Abstract available

ZHOU C, Zhuang Y, Lin X, Michelson AD, et al
Changes in neurocognitive function and central nervous system structure in childhood acute lymphoblastic leukaemia survivors after treatment: a meta-analysis.
Br J Haematol. 2020;188:945-961.
PubMed Abstract available

HOLTZMAN NG, El Chaer F, Baer MR, Ali O, et al
Peripheral blood blast rate of clearance is an independent predictor of clinical response and outcomes in acute myeloid leukaemia.
Br J Haematol. 2020;188:881-887.
PubMed Abstract available

ELSTON L, Fegan C, Hills R, Hashimdeen SS, et al
Increased frequency of CD4(+) PD-1(+) HLA-DR(+) T cells is associated with disease progression in CLL.
Br J Haematol. 2020;188:872-880.
PubMed Abstract available

EYRE TA, Roeker LE, Fox CP, Gohill SH, et al
The efficacy and safety of venetoclax therapy in elderly patients with relapsed, refractory chronic lymphocytic leukaemia.
Br J Haematol. 2020;188:918-923.
PubMed Abstract available

LINCH DC, Hills RK, Burnett AK, Russell N, et al
Analysis of the clinical impact of NPM1 mutant allele burden in a large cohort of younger adult patients with acute myeloid leukaemia.
Br J Haematol. 2020;188:852-859.
PubMed Abstract available

February 2020

DALAL NH, Dores GM, Curtis RE, Linet MS, et al
Cause-specific mortality in individuals with lymphoplasmacytic lymphoma/Waldenstrom macroglobulinaemia, 2000-2016.
Br J Haematol. 2020 Feb 23. doi: 10.1111/bjh.16492.
PubMed Abstract available

MONDELAERS V, Ferster A, Uyttebroeck A, Brichard B, et al
Prospective, real-time monitoring of pegylated Escherichia coli and Erwinia asparaginase therapy in childhood acute lymphoblastic leukaemia and non-Hodgkin lymphoma in Belgium.
Br J Haematol. 2020 Feb 14. doi: 10.1111/bjh.16495.
PubMed Abstract available

ETIENNE G, Dulucq S, Faberes C, Bijou F, et al
A single center evaluation of cost savings related to treatment-free remission in chronic myeloid leukemia patients: the prerequisites of a pharmaco-economy larger study.
Br J Haematol. 2020 Feb 10. doi: 10.1111/bjh.16511.
PubMed

ROMZOVA M, Smitalova D, Tom N, Jurcek T, et al
Novel Illumina-based next generation sequencing approach with one-round amplification provides early and reliable detection of BCR-ABL1 kinase domain mutations in chronic myeloid leukemia.
Br J Haematol. 2020 Feb 9. doi: 10.1111/bjh.16382.
PubMed Abstract available

MATSUO T, Ooi J, Tashiro H, Saito S, et al
A major break of cord blood bag.
Br J Haematol. 2020;188:e42-e43.
PubMed

HOCKINGS C, Gohil S, Dowse R, Hoade Y, et al
In trans early mosaic mutational escape and novel phenotypic features of germline SAMD9 mutation.
Br J Haematol. 2020;188:e53-e57.
PubMed

NILSSON MS, Hallner A, Brune M, Nilsson S, et al
Complete remission after the first cycle of induction chemotherapy determines the clinical efficacy of relapse-preventive immunotherapy in acute myeloid leukaemia.
Br J Haematol. 2020;188:e49-e53.
PubMed

GURNEY M, Krawczyk J, Paz Nunez YE
Megakaryocyte emperipolesis in B-lymphoblastic leukaemia.
Br J Haematol. 2020;188:348.
PubMed

CAPITANO M, Capo-Chichi JM, Minden MD, Chang H, et al
Mixed phenotype acute leukaemia with predominant myeloid blasts and a small subset of B/myeloid blasts shares the same mutation profile.
Br J Haematol. 2020;188:e60-e63.
PubMed

BROWN P, Zugmaier G, Gore L, Tuglus CA, et al
Day 15 bone marrow minimal residual disease predicts response to blinatumomab in relapsed/refractory paediatric B-ALL.
Br J Haematol. 2020;188:e36-e39.
PubMed

DA COSTA VEF, de Oliveira RD, Traina F, Chahud F, et al
Co-occurrence of BCR-ABL1-positive chronic myeloid leukaemia and CALR-mutated essential thrombocythaemia.
Br J Haematol. 2020;188:e21-e23.
PubMed

SHAHSWAR R, Beutel G, Klement P, Rehberg A, et al
FLA-IDA salvage chemotherapy combined with a seven-day course of venetoclax (FLAVIDA) in patients with relapsed/refractory acute leukaemia.
Br J Haematol. 2020;188:e11-e15.
PubMed

BARON F, Labopin M, Savani BN, Beohou E, et al
Graft-versus-host disease and graft-versus-leukaemia effects in secondary acute myeloid leukaemia: a retrospective, multicentre registry analysis from the Acute Leukaemia Working Party of the EBMT.
Br J Haematol. 2020;188:428-437.
PubMed Abstract available

HARA Y, Shiba N, Yamato G, Ohki K, et al
Patients aged less than 3 years with acute myeloid leukaemia characterize a molecularly and clinically distinct subgroup.
Br J Haematol. 2020;188:528-539.
PubMed Abstract available

HANSEN MC, Haferlach T, Nyvold CG
A decade with whole exome sequencing in haematology.
Br J Haematol. 2020;188:367-382.
PubMed Abstract available

January 2020

The Management of Acute Leukaemia in Adults.
Br J Haematol. 2020;188:10-28.
PubMed

DEROLF A, Juliusson G, Benson L, Floisand Y, et al
Decreasing early mortality in acute myeloid leukaemia in Sweden 1997-2014: improving performance status is a major contributing factor.
Br J Haematol. 2020;188:187-191.
PubMed

OLIAI C, Schiller G
How to address second and therapy-related acute myelogenous leukaemia.
Br J Haematol. 2020;188:116-128.
PubMed Abstract available

CHARROT S, Armes H, Rio-Machin A, Fitzgibbon J, et al
AML through the prism of molecular genetics.
Br J Haematol. 2020;188:49-62.
PubMed Abstract available

HILLS RK
Evaluating sixty years of UK trials research in acute myeloid leukaemia: lessons for trial design, past, present and future.
Br J Haematol. 2020;188:29-35.
PubMed Abstract available

PAUL S, Rausch CR, Jabbour EJ
The face of remission induction.
Br J Haematol. 2020;188:101-115.
PubMed Abstract available

BURNETT AK, Hills RK, Russell N
Twenty five years of UK trials in acute myeloid leukaemia: what have we learned?
Br J Haematol. 2020;188:86-100.
PubMed

HOKLAND P
AML - a signature disease in haematology.
Br J Haematol. 2020;188:7.
PubMed

LOKE J, Malladi R, Moss P, Craddock C, et al
The role of allogeneic stem cell transplantation in the management of acute myeloid leukaemia: a triumph of hope and experience.
Br J Haematol. 2020;188:129-146.
PubMed Abstract available

MO X, Chen H
Acute promyelocytic leukaemia with myeloperoxidase-negative rectangular inclusions.
Br J Haematol. 2020;188:8.
PubMed

HAFERLACH T, Schmidts I
The power and potential of integrated diagnostics in acute myeloid leukaemia.
Br J Haematol. 2020;188:36-48.
PubMed Abstract available

GARCIA SPEZZA E, Brethon B, Petit A, Mazingue F, et al
Tolerance to arsenic trioxide combined with all-trans-retinoic acid in children with acute promyelocytic leukaemia in France.
Br J Haematol. 2020;188:170-173.
PubMed

GHOSH A, Barba P, Perales MA
Checkpoint inhibitors in AML: are we there yet?
Br J Haematol. 2020;188:159-167.
PubMed Abstract available

JONES L, McCarthy P, Bond J
Epigenetics of paediatric acute myeloid leukaemia.
Br J Haematol. 2020;188:63-76.
PubMed Abstract available

GHANNAM J, Dillon LW, Hourigan CS
Next-generation sequencing for measurable residual disease detection in acute myeloid leukaemia.
Br J Haematol. 2020;188:77-85.
PubMed Abstract available

WANG T, Wang Z, Zhang L, Wen L, et al
Identification of a novel TFG-FGFR1 fusion gene in an acute myeloid leukaemia patient with t(3;8)(q12;p11).
Br J Haematol. 2020;188:177-181.
PubMed

BARRETT AJ
Acute myeloid leukaemia and the immune system: implications for immunotherapy.
Br J Haematol. 2020;188:147-158.
PubMed Abstract available

PIANIGIANI G, Betti C, Bigerna B, Rossi R, et al
PU.1 subcellular localization in acute myeloid leukaemia with mutated NPM1.
Br J Haematol. 2020;188:184-187.
PubMed

JIANG G, Atenafu EG, Capo-Chichi JM, Minden MD, et al
Prognostic relevance of CD123 expression in adult AML with normal karyotype.
Br J Haematol. 2020;188:181-184.
PubMed

ESPARZA S, Muluneh B, Galeotti J, Matson M, et al
Venetoclax-induced tumour lysis syndrome in acute myeloid leukaemia.
Br J Haematol. 2020;188:173-177.
PubMed

YIN J, Zhu S, Luo Y, Lin Z, et al
Acute myeloid leukaemia with Auer rods within pseudo-Chediak-Higashi granules.
Br J Haematol. 2020;188:9.
PubMed

KATAGIRI S, Gotoh A, Ohyashiki K
Very late relapse with rapid BCR-ABL1 elevation after more than seven years of treatment-free remission with undetectable molecular residual disease in chronic myeloid leukaemia.
Br J Haematol. 2020;188:332-334.
PubMed

RAFEI H, Kantarjian HM, Jabbour EJ
Targeted therapy paves the way for the cure of acute lymphoblastic leukaemia.
Br J Haematol. 2020;188:207-223.
PubMed Abstract available

December 2019

ELITZUR S, Arad-Cohen N, Barg A, Litichever N, et al
Mucormycosis in children with haematological malignancies is a salvageable disease: a report from the Israeli Study Group of Childhood Leukemia.
Br J Haematol. 2019 Dec 29. doi: 10.1111/bjh.16329.
PubMed Abstract available

HUANG H, Qin T, Xu Z, Shi Z, et al
Mutational features of myelodysplastic syndromes with Auer rods reveal them are more akin to acute myeloid leukemia.
Br J Haematol. 2019 Dec 27. doi: 10.1111/bjh.16326.
PubMed

November 2019

ROSADAS C, Puccioni-Sohler M, Oliveira ACP, Casseb J, et al
Adult T-cell leukaemia/lymphoma in Brazil: A rare disease or rarely diagnosed?
Br J Haematol. 2019 Nov 19. doi: 10.1111/bjh.16318.
PubMed

October 2019

NYLAND SB, Feith DJ, Poss M, Olson TL, et al
Retroviral sero-reactivity in LGL leukaemia patients and family members.
Br J Haematol. 2019 Oct 14. doi: 10.1111/bjh.16223.
PubMed Abstract available

July 2019

FERRETTI A, Baldacci E, Miulli E, Canichella M, et al
Thrombopoietin receptor agonists to control immune thrombocytopenia in patients with active lymphoma.
Br J Haematol. 2019 Jul 31. doi: 10.1111/bjh.16114.
PubMed

DOMINGUEZ-PINILLA N, Martinez-Zamorano E, Campos-Martin Y, Algara Plana P, et al
Paediatric-type nodal follicular lymphoma in a child diagnosed with chronic myeloid leukaemia.
Br J Haematol. 2019 Jul 8. doi: 10.1111/bjh.16089.
PubMed

June 2019

SAKAMOTO K, Shiba N, Deguchi T, Kiyokawa N, et al
Negative CD19 expression is associated with inferior relapse-free survival in children with RUNX1-RUNX1T1-positive acute myeloid leukaemia: results from the Japanese Paediatric Leukaemia/Lymphoma Study Group AML-05 study.
Br J Haematol. 2019 Jun 27. doi: 10.1111/bjh.16080.
PubMed Abstract available

May 2019

KHOGEER H, Rahman H, Jain N, Angelova EA, et al
Early T precursor acute lymphoblastic leukaemia/lymphoma shows differential immunophenotypic characteristics including frequent CD33 expression and in vitro response to targeted CD33 therapy.
Br J Haematol. 2019 May 22. doi: 10.1111/bjh.15960.
PubMed Abstract available

TOYODA K, Tsukasaki K, Machida R, Kadota T, et al
Possibility of a risk-adapted treatment strategy for untreated aggressive adult T-cell leukaemia-lymphoma (ATL) based on the ATL prognostic index: a supplementary analysis of the JCOG9801.
Br J Haematol. 2019 May 16. doi: 10.1111/bjh.15950.
PubMed Abstract available

April 2019

THURGOOD LA, Dwyer ES, Lower KM, Chataway TK, et al
Altered expression of metabolic pathways in CLL detected by unlabelled quantitative mass spectrometry analysis.
Br J Haematol. 2019;185:65-78.
PubMed Abstract available

ZHANG J, Li M, He Y
Acute promyelocytic leukaemia with increased basophils.
Br J Haematol. 2019;185:7.
PubMed

VISENTIN A, Imbergamo S, Scomazzon E, Pravato S, et al
BCR kinase inhibitors, idelalisib and ibrutinib, are active and effective in Richter syndrome.
Br J Haematol. 2019;185:193-197.
PubMed

HOKLAND P, Hansen MC
Acute myeloid/T-lymphoblastic leukaemia (ATML) - a disease entity to look out for.
Br J Haematol. 2019;185:178.
PubMed

MILANI G, Matthijssens F, Van Loocke W, Durinck K, et al
Genetic characterization and therapeutic targeting of MYC-rearranged T cell acute lymphoblastic leukaemia.
Br J Haematol. 2019;185:169-174.
PubMed

MORENO C, Delgado J, Byrd JC, Zvagelsky WL, et al
Changes in clinical stage identify patients with CLL and different outcome within iwCLL partial response: RESONATE study.
Br J Haematol. 2019;185:148-150.
PubMed

CABEZAS M, Camos M, Rives S, Garcia-Orad A, et al
Impact of polymorphisms in apoptosis-related genes on the outcome of childhood acute lymphoblastic leukaemia.
Br J Haematol. 2019;185:159-162.
PubMed

NAKASONE H, Tabuchi K, Uchida N, Ohno Y, et al
Which is more important for the selection of cord blood units for haematopoietic cell transplantation: the number of CD34-positive cells or total nucleated cells?
Br J Haematol. 2019;185:166-169.
PubMed

RAPONI S, Del Giudice I, Ilari C, Cafforio L, et al
Biallelic BIRC3 inactivation in chronic lymphocytic leukaemia patients with 11q deletion identifies a subgroup with very aggressive disease.
Br J Haematol. 2019;185:156-159.
PubMed

March 2019

BILL M, Aggerholm A, Kjeldsen E, Roug AS, et al
Revisiting CLEC12A as leukaemic stem cell marker in AML: highlighting the necessity of precision diagnostics in patients eligible for targeted therapy.
Br J Haematol. 2019;184:769-781.
PubMed Abstract available

SCHMID C, Labopin M, Schaap N, Veelken H, et al
Prophylactic donor lymphocyte infusion after allogeneic stem cell transplantation in acute leukaemia - a matched pair analysis by the Acute Leukaemia Working Party of EBMT.
Br J Haematol. 2019;184:782-787.
PubMed Abstract available

TANG FF, Mo XD, Wang Y, Yan CH, et al
Hepatitis E virus infection after haploidentical haematopoietic stem cell transplantation: incidence and clinical course.
Br J Haematol. 2019;184:788-796.
PubMed Abstract available

KABBAGE S, Cupaiolo R, Rozen L, Demulder A, et al
Auer rods in neutrophils in bone marrow and peripheral blood in mixed phenotype acute leukaemia in a child.
Br J Haematol. 2019;184:708.
PubMed

CHENG Y, Chen Y, Yan C, Wang Y, et al
Comments on the article: 'Donor-derived CD19-targeted T cell infusion induces minimal residual disease-negative remission in relapsed B-cell acute lymphoblastic leukaemia with no response to donor lymphocyte infusions after haploidentical haematopoiet
Br J Haematol. 2019;184:882-883.
PubMed

PAN T, Qi J, Liu Y, Wu D, et al
Comments on the article 'Donor-derived CD19-targeted T cell infusion induces minimal residual disease-negative remission in relapsed B-cell acute lymphoblastic leukaemia with no response to donor lymphocyte infusions after haploidentical haematopoieti
Br J Haematol. 2019;184:881-882.
PubMed

CHEN Y, Peubez C, Jayne S, Kocsis-Fodor G, et al
Differential activation of pro-survival pathways in response to CD40LG/IL4 stimulation in chronic lymphocytic leukaemia cells.
Br J Haematol. 2019;184:867-869.
PubMed

DING LW, Tan KT, Sun QY, Lao ZT, et al
Clonality and clonal evolution analysis of paediatric ALL based on B-cell receptor/T-cell receptor rearrangement.
Br J Haematol. 2019;184:829-833.
PubMed

SCHETELIG J, Link CS, Stuhler G, Wagner EM, et al
Anti-CD20 immunotherapy as a bridge to tolerance, after allogeneic stem cell transplantation for patients with chronic lymphocytic leukaemia: results of the CLLX4 trial.
Br J Haematol. 2019;184:833-836.
PubMed

ZUGMAIER G
Aneuploidy in childhood B cell acute lymphoblastic leukaemia - also a relevant prognostic factor in relapsed disease?
Br J Haematol. 2019;184:895-896.
PubMed

NOETZLI J, Voruz S, Wunder D, Primi MP, et al
Ten-year single-centre experience in fertility preservation of 459 patients suffering from acute leukaemia.
Br J Haematol. 2019;184:969-973.
PubMed Abstract available

ZHANG J, Li M, He Y
Granular B-lineage acute lymphoblastic leukaemia mimicking acute myeloid leukaemia.
Br J Haematol. 2019;184:894.
PubMed

OTTMANN OG, Muller-Tidow C, Kramer A, Schlenk RF, et al
Phase I dose-escalation trial investigating volasertib as monotherapy or in combination with cytarabine in patients with relapsed/refractory acute myeloid leukaemia.
Br J Haematol. 2019;184:1018-1021.
PubMed

IFVERSEN M, Turkiewicz D, Marquart HV, Winiarski J, et al
Low burden of minimal residual disease prior to transplantation in children with very high risk acute lymphoblastic leukaemia: The NOPHO ALL2008 experience.
Br J Haematol. 2019;184:982-993.
PubMed Abstract available

BARZILAI-BIRENBOIM S, Arad-Cohen N, Nirel R, Avrahami G, et al
Thrombophilia screening and thromboprophylaxis may benefit specific ethnic subgroups with paediatric acute lymphoblastic leukaemia.
Br J Haematol. 2019;184:994-998.
PubMed Abstract available

IMPROGO MR, Tesar B, Klitgaard JL, Magori-Cohen R, et al
MYD88 L265P mutations identify a prognostic gene expression signature and a pathway for targeted inhibition in CLL.
Br J Haematol. 2019;184:925-936.
PubMed Abstract available

PIREDDA ML, Gaur G, Catalano G, Divona M, et al
PML/RARA inhibits expression of HSP90 and its target AKT.
Br J Haematol. 2019;184:937-948.
PubMed Abstract available

BERGER G, van den Berg E, Smetsers S, Leegte BK, et al
Fanconi anaemia presenting as acute myeloid leukaemia and myelodysplastic syndrome in adulthood: a family report on co-occurring FANCC and CHEK2 mutations.
Br J Haematol. 2019;184:1071-1073.
PubMed

BOMBEN R, Roisman A, D'Agaro T, Castellano G, et al
Expression of the transcribed ultraconserved region 70 and the related long non-coding RNA AC092652.2-202 has prognostic value in Chronic Lymphocytic Leukaemia.
Br J Haematol. 2019;184:1045-1050.
PubMed

AGRAWAL AK, Aguilar A, Feusner J
Unifying the diagnosis of isolated central nervous system relapse in acute lymphoblastic leukaemia based on minimal residual disease testing.
Br J Haematol. 2019;184:1026-1027.
PubMed

February 2019

KHASHAB T, Hagemeister F, Romaguera JE, Fanale MA, et al
Long-term overall- and progression-free survival after pentostatin, cyclophosphamide and rituximab therapy for indolent non-Hodgkin lymphoma.
Br J Haematol. 2019 Feb 28. doi: 10.1111/bjh.15814.
PubMed Abstract available

BURKHARDT B, Hermiston ML
Lymphoblastic lymphoma in children and adolescents: review of current challenges and future opportunities.
Br J Haematol. 2019 Feb 27. doi: 10.1111/bjh.15793.
PubMed Abstract available

MIYAMURA T, Moritake H, Nakayama H, Tanaka S, et al
Clinical and biological features of paediatric acute myeloid leukaemia (AML) with primary induction failure in the Japanese Paediatric Leukaemia/Lymphoma Study Group AML-05 study.
Br J Haematol. 2019 Feb 19. doi: 10.1111/bjh.15799.
PubMed Abstract available

O'REILLY MA, Govender D, Kirkwood AA, Vora A, et al
The incidence of invasive fungal infections in children, adolescents and young adults with acute lymphoblastic leukaemia/lymphoma treated with the UKALL2011 protocol: a multicentre retrospective study.
Br J Haematol. 2019 Feb 15. doi: 10.1111/bjh.15798.
PubMed

MASETTI R, Bertuccio SN, Pession A, Locatelli F, et al
CBFA2T3-GLIS2-positive acute myeloid leukaemia. A peculiar paediatric entity.
Br J Haematol. 2019;184:337-347.
PubMed Abstract available

CHEN D, Camponeschi A, Wu Q, Gerasimcik N, et al
CD99 expression is strongly associated with clinical outcome in children with B-cell precursor acute lymphoblastic leukaemia.
Br J Haematol. 2019;184:418-423.
PubMed Abstract available

HOJFELDT SG, Wolthers BO, Tulstrup M, Abrahamsson J, et al
Genetic predisposition to PEG-asparaginase hypersensitivity in children treated according to NOPHO ALL2008.
Br J Haematol. 2019;184:405-417.
PubMed Abstract available

TIAN C, Yu Y, Zhang Y
Waldenstrom macroglobulinaemia terminating in acute lymphoblastic leukaemia after treatment with fludarabine.
Br J Haematol. 2019;184:322.
PubMed

GUARINI A, Peragine N, Messina M, Marinelli M, et al
Unravelling the suboptimal response of TP53-mutated chronic lymphocytic leukaemia to ibrutinib.
Br J Haematol. 2019;184:392-396.
PubMed Abstract available

KOPP CR, Jandial A, Mishra K, Sandal R, et al
Myasthenia gravis unmasked by imatinib.
Br J Haematol. 2019;184:321.
PubMed

WALLINGTON-BEDDOE CT, Xie V, Tong D, Powell JA, et al
Identification of sphingosine kinase 1 as a therapeutic target in B-lineage acute lymphoblastic leukaemia.
Br J Haematol. 2019;184:443-447.
PubMed

MINETTO P, Guolo F, Clavio M, Kunkl A, et al
Early minimal residual disease assessment after AML induction with fludarabine, cytarabine and idarubicin (FLAI) provides the most useful prognostic information.
Br J Haematol. 2019;184:457-460.
PubMed

BRANDER DM, Friedman DR, Volkheimer AD, Christensen DJ, et al
SET alpha and SET beta mRNA isoforms in chronic lymphocytic leukaemia.
Br J Haematol. 2019;184:605-615.
PubMed Abstract available

GALEOTTI J, Coombs CC
Enasidenib-induced eosinophilic differentiation in a patient with acute myeloid leukaemia with IDH2 and U2AF1 mutations.
Br J Haematol. 2019;184:496.
PubMed

KARUNAKARAN P, Yanamandra U, Nampoothiri RV, Khadwal A, et al
Early detection of differentiation syndrome by chest ultrasound in acute promyelocytic leukaemia.
Br J Haematol. 2019;184:672-673.
PubMed

COLLORD G, Martincorena I, Young MD, Foroni L, et al
Recurrent histone mutations in T-cell acute lymphoblastic leukaemia.
Br J Haematol. 2019;184:676-679.
PubMed

OFRAN Y, Beohou E, Labopin M, Blaise D, et al
Anti-thymocyte globulin for graft-versus-host disease prophylaxis in patients with intermediate- or high-risk acute myeloid leukaemia undergoing reduced-intensity conditioning allogeneic stem cell transplantation in first complete remission - a survey
Br J Haematol. 2019;184:643-646.
PubMed

FURNESS CL, Kirkwood A, Rowntree C, Vora A, et al
Early morphological response is significantly associated with, but does not accurately predict, relapse in teenagers and young adults aged 10-24 years with acute lymphoblastic leukaemia (ALL): results from UKALL2003.
Br J Haematol. 2019;184:663-666.
PubMed

EYRE TA, Fox CP, Boden A, Bloor A, et al
Idelalisib-rituximab induces durable remissions in TP53 disrupted B-PLL but results in significant toxicity: updated results of the UK-wide compassionate use programme.
Br J Haematol. 2019;184:667-671.
PubMed

PINTO AM, Papa FT, Frullanti E, Meloni I, et al
Low-level TP53 mutational load antecedes clonal expansion in chronic lymphocytic leukaemia.
Br J Haematol. 2019;184:657-659.
PubMed

January 2019

BATALLER A, Combalia A, Garcia-Herrera A, Estrach T, et al
Isolated cutaneous lymphomatous form of adult T-cell leukaemia/lymphoma.
Br J Haematol. 2019 Jan 6. doi: 10.1111/bjh.15744.
PubMed

KHAKWANI M, Srinath S, Pratt G, Moss P, et al
A rare complication of bone marrow aspiration and trephine biopsy: Staphylococcus aureus osteomyelitis and septicaemia.
Br J Haematol. 2019;184:7.
PubMed

HU AY, Zhou T
Sequential B-lymphoid and myeloid blastic transformation of Philadelphia chromosome-negative myeloproliferative neoplasm.
Br J Haematol. 2019;184:8.
PubMed

November 2018

BRIERLEY CK, Jones FM, Hanlon K, Peniket AJ, et al
Impact of graft-versus-lymphoma effect on outcomes after reduced intensity conditioned-alemtuzumab allogeneic haematopoietic stem cell transplantation for patients with mature lymphoid malignancies.
Br J Haematol. 2018 Nov 22. doi: 10.1111/bjh.15685.
PubMed Abstract available

August 2018

SU C, Bai HX, Xiao R
HTLV-1 status should be recorded in cases of T cell lymphomas/lymphoproliferative disorders - cases of adult T cell leukaemia lymphoma masquerading as other T cell lymphomas/lymphoproliferative disorders could explain some of the apparent ethnic dispa
Br J Haematol. 2018 Aug 3. doi: 10.1111/bjh.15526.
PubMed

LO BELLO G, Naresh KN
HTLV-1 status should be recorded in cases of T cell lymphomas/lymphoproliferative disorders - cases of adult T cell leukaemia lymphoma masquerading as other T cell lymphomas/lymphoproliferative disorders could explain some apparent ethnic disparities.
Br J Haematol. 2018 Aug 3. doi: 10.1111/bjh.15527.
PubMed

July 2018

AILAWADHI S, Dholaria BR, Khurana S, Sher T, et al
Outcomes of patients with simultaneous diagnosis of chronic lymphocytic leukaemia/small lymphocytic lymphoma and multiple myeloma.
Br J Haematol. 2018 Jul 5. doi: 10.1111/bjh.15458.
PubMed

June 2018

YEOH AE, Li Z, Dong D, Lu Y, et al
Effective Response Metric: a novel tool to predict relapse in childhood acute lymphoblastic leukaemia using time-series gene expression profiling.
Br J Haematol. 2018;181:653-663.
PubMed Abstract available

MOZESSOHN L, Cheung MC, Fallahpour S, Gill T, et al
Azacitidine in the 'real-world': an evaluation of 1101 higher-risk myelodysplastic syndrome/low blast count acute myeloid leukaemia patients in Ontario, Canada.
Br J Haematol. 2018;181:803-815.
PubMed Abstract available

ZHOU W, Goldin L, Wang M, McMaster ML, et al
Combined somatic mutation and copy number analysis in the survival of familial CLL.
Br J Haematol. 2018;181:604-613.
PubMed Abstract available

CHIARETTI S, Messina M, Grammatico S, Piciocchi A, et al
Rapid identification of BCR/ABL1-like acute lymphoblastic leukaemia patients using a predictive statistical model based on quantitative real time-polymerase chain reaction: clinical, prognostic and therapeutic implications.
Br J Haematol. 2018;181:642-652.
PubMed Abstract available

BLAYNEY JK, Mills KI
Compositional analysis gives insight into leukaemia cell lines expression profiles compared to those within patient sub-groups.
Br J Haematol. 2018;181:847-851.
PubMed

AW A, Hellman JM, Birner A, Davids MS, et al
A complex case of ibrutinib treatment for a CLL patient on haemodialysis.
Br J Haematol. 2018;181:854-857.
PubMed

MCCLAIN CA, Bernhardt MB, Berger A, Bernini JC, et al
Pharmacogenetic association with neurotoxicity in Hispanic children with acute lymphoblastic leukaemia.
Br J Haematol. 2018;181:684-687.
PubMed

GHIONE P, Genuardi E, Rossi D, Drandi D, et al
Progressive telomere shortening is part of the natural history of chronic lymphocytic leukaemia and impacts clinical outcome: evidences from long term follow-up.
Br J Haematol. 2018;181:693-695.
PubMed

MEI H, Jiang H, Wu Y, Guo T, et al
Neurological toxicities and coagulation disorders in the cytokine release syndrome during CAR-T therapy.
Br J Haematol. 2018;181:689-692.
PubMed

May 2018

SUTTON R
Age matters in ALL.
Br J Haematol. 2018;181:429-430.
PubMed

SELLAR RS, Rowntree C, Vora AJ, Furness CL, et al
Relapse in teenage and young adult patients treated on a paediatric minimal residual disease stratified ALL treatment protocol is associated with a poor outcome: results from UKALL2003.
Br J Haematol. 2018;181:515-522.
PubMed Abstract available

SELLAR RS, Gale RE, Khwaja A, Garbowski M, et al
Immunophenotypic analysis of cell cycle status in acute myeloid leukaemia: relationship to cytogenetics, genotype and clinical outcome.
Br J Haematol. 2018;181:486-494.
PubMed Abstract available

KASPERS GJL, Niewerth D, Wilhelm BAJ, Scholte-van Houtem P, et al
An effective modestly intensive re-induction regimen with bortezomib in relapsed or refractory paediatric acute lymphoblastic leukaemia.
Br J Haematol. 2018;181:523-527.
PubMed Abstract available

JIMENEZ JJ, DelCanto GM, Popovics P, Perez A, et al
A new approach to the treatment of acute myeloid leukaemia targeting the receptor for growth hormone-releasing hormone.
Br J Haematol. 2018;181:476-485.
PubMed Abstract available

LI S, Zhang J, Wang M, Fu G, et al
Treatment of acute lymphoblastic leukaemia with the second generation of CD19 CAR-T containing either CD28 or 4-1BB.
Br J Haematol. 2018;181:360-371.
PubMed Abstract available

PORPACZY E, Skrabs C, Schwarzinger I, Augustin D, et al
Increased lymphocyte cell size with blastoid morphology associated with splenic rupture following cessation of ibrutinib.
Br J Haematol. 2018;181:431.
PubMed

KURT H, Khoury JD, Medeiros LJ, Huh YO, et al
Blastic plasmacytoid dendritic cell neoplasm with unusual morphology, MYC rearrangement and TET2 and DNMT3A mutations.
Br J Haematol. 2018;181:305.
PubMed

LOHSE S, Loew S, Kretschmer A, Jansen JHM, et al
Effector mechanisms of IgA antibodies against CD20 include recruitment of myeloid cells for antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity.
Br J Haematol. 2018;181:413-417.
PubMed

MARTINEZ-LAPERCHE C, Kwon M, Franco-Villegas AC, Chillon MC, et al
Wilms Tumor 1 gene expression levels improve risk stratification in AML patients. Results of a multicentre study within the Spanish Group for Molecular Biology in Haematology.
Br J Haematol. 2018;181:542-546.
PubMed

April 2018

FRIDTHJOF KS, Kampmann P, Dunweber A, Gorlov JS, et al
Systematic patient involvement for homebased outpatient administration of complex chemotherapy in acute leukemia and lymphoma.
Br J Haematol. 2018 Apr 20. doi: 10.1111/bjh.15249.
PubMed Abstract available

MALIK B, Taylor GP
Can we reduce the incidence of adult T-cell leukaemia/lymphoma? Cost-effectiveness of human T-lymphotropic virus type 1 (HTLV-1) antenatal screening in the United Kingdom.
Br J Haematol. 2018 Apr 20. doi: 10.1111/bjh.15234.
PubMed

CITRIN R, Getz KD, Li Y, Huang YS, et al
The epidemiology of rasburicase use in paediatric patients with acute lymphoblastic leukaemia and non-Hodgkin lymphoma.
Br J Haematol. 2018 Apr 2. doi: 10.1111/bjh.15159.
PubMed

RIGOLIN GM, Saccenti E, Guardalben E, Cavallari M, et al
In chronic lymphocytic leukaemia with complex karyotype, major structural abnormalities identify a subset of patients with inferior outcome and distinct biological characteristics.
Br J Haematol. 2018;181:229-233.
PubMed Abstract available

OSTGARD LSG, Norgaard M, Pedersen L, Ostgard RD, et al
Autoimmune diseases, infections, use of antibiotics and the risk of acute myeloid leukaemia: a national population-based case-control study.
Br J Haematol. 2018;181:205-214.
PubMed Abstract available

CRASSINI KR, Zhang E, Balendran S, Freeman JA, et al
Humoral immune failure defined by immunoglobulin class and immunoglobulin G subclass deficiency is associated with shorter treatment-free and overall survival in Chronic Lymphocytic Leukaemia.
Br J Haematol. 2018;181:97-101.
PubMed Abstract available

HOBO W, Hutten TJA, Schaap NPM, Dolstra H, et al
Immune checkpoint molecules in acute myeloid leukaemia: managing the double-edged sword.
Br J Haematol. 2018;181:38-53.
PubMed Abstract available

RASHIDI A, Weisdorf DJ, Bejanyan N
Treatment of relapsed/refractory acute myeloid leukaemia in adults.
Br J Haematol. 2018;181:27-37.
PubMed Abstract available

SHRUBSOLE C, Collin M
Tumour genesis syndrome in relapsed B lymphoblastic leukaemia.
Br J Haematol. 2018;181:160.
PubMed

DEMYANETS S, Jaeger E, Pablik E, Greiner G, et al
The JAK2 blocker TG101209 is a potent inhibitor of clonogenic progenitor cell growth in patients with chronic myeloid leukaemia.
Br J Haematol. 2018;181:137-139.
PubMed

MATO AR, Timlin C, Ujjani C, Skarbnik A, et al
Comparable outcomes in chronic lymphocytic leukaemia (CLL) patients treated with reduced-dose ibrutinib: results from a multi-centre study.
Br J Haematol. 2018;181:259-261.
PubMed

LIAO K, Zheng Z, Yang L, Wang L, et al
Analysis of high-resolution human leucocyte antigen allele polymorphism in 3788 Han Chinese patients with leukaemia.
Br J Haematol. 2018;181:278-281.
PubMed

ARAI H, Nobusawa S, Kawabata-Iwakawa R, Rokudai S, et al
Myeloid sarcoma arising in malignant phyllodes tumour: clonal relationships revealed by comparative genome-wide analyses.
Br J Haematol. 2018;181:255-259.
PubMed

MOLICA M, Breccia M, Colafigli G, Massaro F, et al
Long-term impact of molecular response fluctuations in chronic myeloid leukaemia patients treated with imatinib.
Br J Haematol. 2018;181:275-278.
PubMed

SORA F, Iurlo A, Sica S, Latagliata R, et al
Chronic myeloid leukaemia with extreme thrombocytosis at presentation: incidence, clinical findings and outcome.
Br J Haematol. 2018;181:267-270.
PubMed

SOLER AM, Olano N, Mendez Y, Lopes A, et al
TPMT and NUDT15 genes are both related to mercaptopurine intolerance in acute lymphoblastic leukaemia patients from Uruguay.
Br J Haematol. 2018;181:252-255.
PubMed

SCHULZ E, Lind K, Renner W, Petersen BS, et al
The TP53 Pro72Arg SNP in de novo acute myeloid leukaemia - results of two cohort studies involving 215 patients and 3759 controls.
Br J Haematol. 2018;181:148-151.
PubMed

March 2018

VAN TIENEN C, Visser O, Lugtenburg P, Taylor G, et al
Overrepresentation of patients from HTLV-1 endemic countries among T cell Non-Hodgkin lymphomas in the Netherlands: an indication of under-diagnosis of Adult T cell leukaemia/lymphoma.
Br J Haematol. 2018 Mar 12. doi: 10.1111/bjh.15160.
PubMed

LOVISA F, Zecca M, Rossi B, Campeggio M, et al
Pre- and post-transplant minimal residual disease predicts relapse occurrence in children with acute lymphoblastic leukaemia.
Br J Haematol. 2018;180:680-693.
PubMed Abstract available

GRIBBEN JG, Bosch F, Cymbalista F, Geisler CH, et al
Optimising outcomes for patients with chronic lymphocytic leukaemia on ibrutinib therapy: European recommendations for clinical practice.
Br J Haematol. 2018;180:666-679.
PubMed Abstract available

OHANIAN M, Pemmaraju N, Rozovski U, Alattar ML, et al
Ocular extramedullary myeloid leukaemia.
Br J Haematol. 2018;180:738-740.
PubMed

STECKEL NK, Groth C, Mikesch JH, Trenschel R, et al
High-dose melphalan-based sequential conditioning chemotherapy followed by allogeneic haematopoietic stem cell transplantation in adult patients with relapsed or refractory acute myeloid leukaemia.
Br J Haematol. 2018;180:840-853.
PubMed Abstract available

GUTIERREZ A, Kentsis A
Acute myeloid/T-lymphoblastic leukaemia (AMTL): a distinct category of acute leukaemias with common pathogenesis in need of improved therapy.
Br J Haematol. 2018;180:919-924.
PubMed Abstract available

KONG Y, Song Y, Tang FF, Zhao HY, et al
N-acetyl-L-cysteine improves mesenchymal stem cell function in prolonged isolated thrombocytopenia post-allotransplant.
Br J Haematol. 2018;180:863-878.
PubMed Abstract available

JURCZYSZYN A, Radocha J, Davila J, Fiala MA, et al
Prognostic indicators in primary plasma cell leukaemia: a multicentre retrospective study of 117 patients.
Br J Haematol. 2018;180:831-839.
PubMed Abstract available

GUZELKUCUK Z, Isik M, Ozcan AS, Demirkan TH, et al
Imatinib-related interstitial lung disease.
Br J Haematol. 2018;180:780.
PubMed

DUTTA A, Yan D, Hutchison RE, Mohi G, et al
STAT3 mutations are not sufficient to induce large granular lymphocytic leukaemia in mice.
Br J Haematol. 2018;180:911-915.
PubMed

LANGE AP, Lima AS, Lucena-Araujo AR, Jacomo RH, et al
The experience of the International Consortium on Acute Promyelocytic Leukemia in monitoring minimal residual disease in acute promyelocytic leukaemia.
Br J Haematol. 2018;180:915-918.
PubMed

GIONA F, Saglio G, Santopietro M, Menna G, et al
Early response does not predict outcome in children and adolescents with chronic myeloid leukaemia treated with high-dose imatinib.
Br J Haematol. 2018;180:895-898.
PubMed

February 2018

ISHIDA T, Jo T, Takemoto S, Suzushima H, et al
Follow-up of a randomised phase II study of chemotherapy alone or in combination with mogamulizumab in newly diagnosed aggressive adult T-cell leukaemia-lymphoma: impact on allogeneic haematopoietic stem cell transplantation.
Br J Haematol. 2018 Feb 7. doi: 10.1111/bjh.15123.
PubMed

STOLZEL F
From remission to cure: bypass or detour?
Br J Haematol. 2018;180:317-318.
PubMed

SUTTON R, Venn NC, Law T, Boer JM, et al
A risk score including microdeletions improves relapse prediction for standard and medium risk precursor B-cell acute lymphoblastic leukaemia in children.
Br J Haematol. 2018;180:550-562.
PubMed Abstract available

KAYSER S, Levis MJ
Advances in targeted therapy for acute myeloid leukaemia.
Br J Haematol. 2018;180:484-500.
PubMed Abstract available

HSU YT, Chen TY
Relapsing polychondritis as a presenting feature of acute myeloid leukaemia.
Br J Haematol. 2018;180:472.
PubMed

ROUTLEDGE DJM, Tower C, Davies E, Scott M, et al
Successful management of acute myeloid leukaemia in a twin pregnancy - a case report.
Br J Haematol. 2018;180:605-606.
PubMed

SIVINA M, Werner L, Rassenti L, Ferrajoli A, et al
Dynamic changes in CCL3 and CCL4 plasma concentrations in patients with chronic lymphocytic leukaemia managed with observation.
Br J Haematol. 2018;180:597-600.
PubMed

MAHDI AJ, Gosrani D, Chakraborty M, Rees A, et al
Successful molecular targeted treatment of AML in pregnancy with Azacitidine and Sorafenib with no adverse fetal outcomes.
Br J Haematol. 2018;180:603-604.
PubMed

CONY-MAKHOUL P, Gardembas M, Coiteux V, Carpentier N, et al
Nilotinib after imatinib first-line: a real-life longitudinal cohort of patients with chronic myeloid leukaemia in chronic phase.
Br J Haematol. 2018;180:356-364.
PubMed Abstract available

DAVIES JK, Hassan S, Sarker SJ, Besley C, et al
Durable graft-versus-leukaemia effects without donor lymphocyte infusions - results of a phase II study of sequential T-replete allogeneic transplantation for high-risk acute myeloid leukaemia and myelodysplasia.
Br J Haematol. 2018;180:346-355.
PubMed Abstract available

TANG FF, Xu LP, Zhang XH, Chen H, et al
Monitoring of post-transplant CBFB-MYH11 as minimal residual disease, rather than KIT mutations, can predict relapse after allogeneic haematopoietic cell transplantation in adults with inv(16) acute myeloid leukaemia.
Br J Haematol. 2018;180:448-451.
PubMed

January 2018

GOCKE CD, Gladstone DE
The absolute percent deviation of IGHV mutation rather than a 98% cut-off predicts survival of chronic lymphocytic leukaemia patients treated with fludarabine, cyclophosphamide and rituximab.
Br J Haematol. 2018;180:7-8.
PubMed

KUHLEN M, Willasch AM, Dalle JH, Wachowiak J, et al
Outcome of relapse after allogeneic HSCT in children with ALL enrolled in the ALL-SCT 2003/2007 trial.
Br J Haematol. 2018;180:82-89.
PubMed Abstract available

ROGERS KA, Huang Y, Ruppert AS, Salem G, et al
A single-institution retrospective cohort study of first-line R-EPOCH chemoimmunotherapy for Richter syndrome demonstrating complex chronic lymphocytic leukaemia karyotype as an adverse prognostic factor.
Br J Haematol. 2018;180:259-266.
PubMed Abstract available

JAIN P, Nogueras Gonzalez GM, Kanagal-Shamanna R, Rozovski U, et al
The absolute percent deviation of IGHV mutation rather than a 98% cut-off predicts survival of chronic lymphocytic leukaemia patients treated with fludarabine, cyclophosphamide and rituximab.
Br J Haematol. 2018;180:33-40.
PubMed Abstract available

REA D, Mahon FX
How I manage relapse of chronic myeloid leukaemia after stopping tyrosine kinase inhibitor therapy.
Br J Haematol. 2018;180:24-32.
PubMed Abstract available

ARUGA Y, Arakawa A, Ono K, Ogawa C, et al
Pseudo-Chediak-Higashi granules and Auer rods in mixed phenotype acute leukaemia, T/myeloid, not otherwise specified.
Br J Haematol. 2018;180:175.
PubMed

WANG J, Morrissette J, Lieberman DB, Timlin C, et al
Utilization of next generation sequencing identifies potentially actionable mutations in chronic lymphocytic leukaemia.
Br J Haematol. 2018;180:299-301.
PubMed

BENNETT CL, Berger JR, Sartor O, Carson KR, et al
Progressive multi-focal leucoencephalopathy among ibrutinib-treated persons with chronic lymphocytic leukaemia.
Br J Haematol. 2018;180:301-304.
PubMed

IBERRI DJ, Kwong BY, Stevens LA, Coutre SE, et al
Ibrutinib-associated rash: a single-centre experience of clinicopathological features and management.
Br J Haematol. 2018;180:164-166.
PubMed

DIAMANTI P, Cox CV, Moppett JP, Blair A, et al
Dual targeting of Hsp90 in childhood acute lymphoblastic leukaemia.
Br J Haematol. 2018;180:147-149.
PubMed

December 2017

WOLACH O, Amitai I, DeAngelo DJ
Current challenges and opportunities in treating adult patients with Philadelphia-negative acute lymphoblastic leukaemia.
Br J Haematol. 2017;179:705-723.
PubMed Abstract available

PAVIGLIANITI A, Ruggeri A, Volt F, Sanz G, et al
Evaluation of a disease risk index for adult patients undergoing umbilical cord blood transplantation for haematological malignancies.
Br J Haematol. 2017;179:790-801.
PubMed Abstract available

KHARFAN-DABAJA MA, Al Malki MM, Deotare U, Raj RV, et al
Haematopoietic cell transplantation for blastic plasmacytoid dendritic cell neoplasm: a North American multicentre collaborative study.
Br J Haematol. 2017;179:781-789.
PubMed Abstract available

ITTEL A, Gervais C, Galoisy AC, M'Kacher R, et al
Triradial and quadriradial chromosomes detected in a case of B-cell prolymphocytic leukaemia.
Br J Haematol. 2017;179:704.
PubMed

RAU RE, Carroll AJ, Heerema NA, Arland L, et al
Klinefelter syndrome and 47,XYY syndrome in children with B cell acute lymphoblastic leukaemia.
Br J Haematol. 2017;179:843-846.
PubMed

November 2017

KOHNKE T, Wittmann VK, Bucklein VL, Lichtenegger F, et al
Diagnosis of CLL revisited: increased specificity by a modified five-marker scoring system including CD200.
Br J Haematol. 2017;179:480-487.
PubMed Abstract available

WU B, Slabicki M, Sellner L, Dietrich S, et al
MED12 mutations and NOTCH signalling in chronic lymphocytic leukaemia.
Br J Haematol. 2017;179:421-429.
PubMed Abstract available

CHEN Y, Cheng Y, Suo P, Yan C, et al
Donor-derived CD19-targeted T cell infusion induces minimal residual disease-negative remission in relapsed B-cell acute lymphoblastic leukaemia with no response to donor lymphocyte infusions after haploidentical haematopoietic stem cell transplantati
Br J Haematol. 2017;179:598-605.
PubMed Abstract available

IGWE IJ, Yang D, Merchant A, Merin N, et al
The presence of Philadelphia chromosome does not confer poor prognosis in adult pre-B acute lymphoblastic leukaemia in the tyrosine kinase inhibitor era - a surveillance, epidemiology, and end results database analysis.
Br J Haematol. 2017;179:618-626.
PubMed Abstract available

DONADIEU J, Beaupain B, Fenneteau O, Bellanne-Chantelot C, et al
Congenital neutropenia in the era of genomics: classification, diagnosis, and natural history.
Br J Haematol. 2017;179:557-574.
PubMed Abstract available

MEDINGER M, Passweg JR
Acute myeloid leukaemia genomics.
Br J Haematol. 2017;179:530-542.
PubMed Abstract available

BUSSI C, Iribarren P, Rodriguez CM
Microtubule-associated protein 1A/1B-light chain 3 (LC3) 'decorates' intracytoplasmic inclusions in a patient with chronic lymphocytic leukaemia.
Br J Haematol. 2017;179:529.
PubMed

NAITHANI R
Dasatinib-induced loss of eyebrows.
Br J Haematol. 2017;179:362.
PubMed

DUTTON D, Roach H, Lowry L
Splenic rupture following temporary cessation of ibrutinib.
Br J Haematol. 2017;179:361.
PubMed

MUSGRAVE KM, van Delft FW, Avery PJ, Clack RM, et al
Cerebral sinovenous thrombosis in children and young adults with acute lymphoblastic leukaemia - a cohort study from the United Kingdom.
Br J Haematol. 2017;179:667-669.
PubMed

GORDON MJ, Raess PW, Young K, Spurgeon SEF, et al
Ibrutinib is an effective treatment for B-cell prolymphocytic leukaemia.
Br J Haematol. 2017;179:501-503.
PubMed

ABID MB, De Mel S
Does ponatinib cross the blood-brain barrier?
Br J Haematol. 2017;179:497-498.
PubMed

October 2017

HAN LJ, Wang Y, Fan ZP, Huang F, et al
Haploidentical transplantation compared with matched sibling and unrelated donor transplantation for adults with standard-risk acute lymphoblastic leukaemia in first complete remission.
Br J Haematol. 2017;179:120-130.
PubMed Abstract available

EWINS K, Malone A, Phelan E, Webb D, et al
Nelarabine-induced peripheral and central neurotoxicity: can sequential MRI brain imaging help to define its natural history?
Br J Haematol. 2017;179:294-297.
PubMed Abstract available

STELLRECHT CM, Chen LS, Ayres ML, Dennison JB, et al
Chlorinated adenosine analogue induces AMPK and autophagy in chronic lymphocytic leukaemia cells during therapy.
Br J Haematol. 2017;179:266-271.
PubMed Abstract available

EDLINGER L, Berger-Becvar A, Menzl I, Hoermann G, et al
Expansion of BCR/ABL1+ cells requires PAK2 but not PAK1.
Br J Haematol. 2017;179:229-241.
PubMed Abstract available

HUGHES TP, Munhoz E, Aurelio Salvino M, Ong TC, et al
Nilotinib dose-optimization in newly diagnosed chronic myeloid leukaemia in chronic phase: final results from ENESTxtnd.
Br J Haematol. 2017;179:219-228.
PubMed Abstract available

MO XD, Lv M, Huang XJ
Preventing relapse after haematopoietic stem cell transplantation for acute leukaemia: the role of post-transplantation minimal residual disease (MRD) monitoring and MRD-directed intervention.
Br J Haematol. 2017;179:184-197.
PubMed Abstract available

MALONE A, Smith OP
Nelarabine toxicity in children and adolescents with relapsed/refractory T-ALL/T-LBL: can we avoid throwing the baby out with the bathwater?
Br J Haematol. 2017;179:179-181.
PubMed

YANAGISAWA R, Ogiso Y, Yoshikawa K, Tanaka M, et al
Myelomonocytic differentiation associated with NPM1-RARA rearrangement.
Br J Haematol. 2017;179:183.
PubMed

SCHEFFOLD A, Jebaraj BMC, Jaramillo S, Tausch E, et al
Impact of telomere length on the outcome of allogeneic stem cell transplantation for poor-risk chronic lymphocytic leukaemia: results from the GCLLSG CLL3X trial.
Br J Haematol. 2017;179:342-346.
PubMed

September 2017

ALVAREZ-LARRAN A, Senin A, Fernandez-Rodriguez C, Pereira A, et al
Impact of genotype on leukaemic transformation in polycythaemia vera and essential thrombocythaemia.
Br J Haematol. 2017;178:764-771.
PubMed Abstract available

ZHANG X, Yang L, Liu X, Nie Z, et al
Research on the epigenetic regulation mechanism of the PTPN6 gene in advanced chronic myeloid leukaemia.
Br J Haematol. 2017;178:728-738.
PubMed Abstract available

FENAUX P, Muus P, Kantarjian H, Lyons RM, et al
Romiplostim monotherapy in thrombocytopenic patients with myelodysplastic syndromes: long-term safety and efficacy.
Br J Haematol. 2017;178:906-913.
PubMed Abstract available

GOCKERITZ E, Vondey V, Guastafierro A, Pizevska M, et al
Establishing a chemical genetic link between Bruton tyrosine kinase activity in malignant B cells and cell functions involved in the micro-environmental dialogue.
Br J Haematol. 2017;178:949-953.
PubMed Abstract available

GHAMLOUCH H, Nguyen-Khac F, Bernard OA
Chronic lymphocytic leukaemia genomics and the precision medicine era.
Br J Haematol. 2017;178:852-870.
PubMed Abstract available

KANTOROVA B, Malcikova J, Brazdilova K, Borsky M, et al
Single cell analysis revealed a coexistence of NOTCH1 and TP53 mutations within the same cancer cells in chronic lymphocytic leukaemia patients.
Br J Haematol. 2017;178:979-982.
PubMed

VAN DER HELM LH, Berger G, Diepstra A, Huls G, et al
Overexpression of TP53 is associated with poor survival, but not with reduced response to hypomethylating agents in older patients with acute myeloid leukaemia.
Br J Haematol. 2017;178:810-812.
PubMed

TRACY I, Tapper W, Parker A, Gardiner A, et al
Type C TP53-CDKN1A pathway dysfunction occurs independently of CDKN1A gene polymorphisms in chronic lymphocytic leukaemia and is associated with TP53 abnormalities.
Br J Haematol. 2017;178:824-826.
PubMed

August 2017

DUROT E, Tomowiak C, Michallet AS, Dupuis J, et al
Transformed Waldenstrom macroglobulinaemia: clinical presentation and outcome. A multi-institutional retrospective study of 77 cases from the French Innovative Leukemia Organization (FILO).
Br J Haematol. 2017 Aug 2. doi: 10.1111/bjh.14881.
PubMed Abstract available

ZWAAN CM, Kowalczyk J, Schmitt C, Bielorai B, et al
Safety and efficacy of nelarabine in children and young adults with relapsed or refractory T-lineage acute lymphoblastic leukaemia or T-lineage lymphoblastic lymphoma: results of a phase 4 study.
Br J Haematol. 2017 Aug 2. doi: 10.1111/bjh.14874.
PubMed Abstract available

SCHETELIG J, de Wreede LC, Andersen NS, Moreno C, et al
Centre characteristics and procedure-related factors have an impact on outcomes of allogeneic transplantation for patients with CLL: a retrospective analysis from the European Society for Blood and Marrow Transplantation (EBMT).
Br J Haematol. 2017;178:521-533.
PubMed Abstract available

STRATI P, Parikh SA, Chaffee KG, Kay NE, et al
Relationship between co-morbidities at diagnosis, survival and ultimate cause of death in patients with chronic lymphocytic leukaemia (CLL): a prospective cohort study.
Br J Haematol. 2017;178:394-402.
PubMed Abstract available

ZELLER B, Glosli H, Forestier E, Ha SY, et al
Hyperleucocytosis in paediatric acute myeloid leukaemia - the challenge of white blood cell counts above 200 x 109 /l. The NOPHO experience 1984-2014.
Br J Haematol. 2017;178:448-456.
PubMed Abstract available

KARLSSON L, Forestier E, Hasle H, Jahnukainen K, et al
Outcome after intensive reinduction therapy and allogeneic stem cell transplant in paediatric relapsed acute myeloid leukaemia.
Br J Haematol. 2017;178:592-602.
PubMed Abstract available

MESSINA M, Chiaretti S, Fedullo AL, Piciocchi A, et al
Clinical significance of recurrent copy number aberrations in B-lineage acute lymphoblastic leukaemia without recurrent fusion genes across age cohorts.
Br J Haematol. 2017;178:583-587.
PubMed Abstract available

EYRE TA, Schuh A
An update for Richter syndrome - new directions and developments.
Br J Haematol. 2017;178:508-520.
PubMed Abstract available

SHVIDEL L
Relationship between comorbidities at diagnosis, survival and ultimate cause of death in patients with chronic lymphocytic leukaemia (CLL): a prospective cohort study.
Br J Haematol. 2017;178:347-348.
PubMed

KWONG JHY, Leung RYY, Wong MLG, Gill H, et al
Primary myelofibrosis presenting in acute promyelocytic transformation.
Br J Haematol. 2017;178:349.
PubMed

TAN RMR, Ganau M, Jeelani NUO, Tahir Z, et al
Central nervous system aspergillosis resembling haemorrhagic brain infarct in a paediatric leukaemia patient.
Br J Haematol. 2017;178:642-645.
PubMed

July 2017

CHEN Y, Pourabdollah M, Chang H
Acute myeloid leukemia with mutated NPM1 demonstrating multilineage dysplasia and marked thrombocytosis.
Br J Haematol. 2017 Jul 5. doi: 10.1111/bjh.14741.
PubMed

THEUNISSEN PMJ, van den Branden A, Van Der Sluijs-Gelling A, De Haas V, et al
Understanding the reconstitution of the B-cell compartment in bone marrow and blood after treatment for B-cell precursor acute lymphoblastic leukaemia.
Br J Haematol. 2017;178:267-278.
PubMed Abstract available

WILLIAMS J, Heppel NH, Britt-Compton B, Grimstead JW, et al
Telomere length is an independent prognostic marker in MDS but not in de novo AML.
Br J Haematol. 2017;178:240-249.
PubMed Abstract available

ARAI Y, Kondo T, Shigematsu A, Tanaka J, et al
Increased non-relapse mortality due to high-dose cytarabine plus CY/TBI in BMT/PBSCT for acute lymphoblastic leukaemia in adults.
Br J Haematol. 2017;178:106-111.
PubMed Abstract available

MARTINI V, Gattazzo C, Frezzato F, Trimarco V, et al
Cortactin, a Lyn substrate, is a checkpoint molecule at the intersection of BCR and CXCR4 signalling pathway in chronic lymphocytic leukaemia cells.
Br J Haematol. 2017;178:81-93.
PubMed Abstract available

THEUNISSEN PMJ, Sedek L, De Haas V, Szczepanski T, et al
Detailed immunophenotyping of B-cell precursors in regenerating bone marrow of acute lymphoblastic leukaemia patients: implications for minimal residual disease detection.
Br J Haematol. 2017;178:257-266.
PubMed Abstract available

SOARES M, Saussoy P, Maskens M, Reul H, et al
Eliminating malignant cells from cryopreserved ovarian tissue is possible in leukaemia patients.
Br J Haematol. 2017;178:231-239.
PubMed Abstract available

JONES JA, Hillmen P, Coutre S, Tam C, et al
Use of anticoagulants and antiplatelet in patients with chronic lymphocytic leukaemia treated with single-agent ibrutinib.
Br J Haematol. 2017;178:286-291.
PubMed Abstract available

STRATI P, Parikh SA, Chaffee KG, Achenbach SJ, et al
CD49d associates with nodal presentation and subsequent development of lymphadenopathy in patients with chronic lymphocytic leukaemia.
Br J Haematol. 2017;178:99-105.
PubMed Abstract available

TSUKAMOTO S, Kumazoe M, Huang Y, Lesnick C, et al
SphK1 inhibitor potentiates the anti-cancer effect of EGCG on leukaemia cells.
Br J Haematol. 2017;178:155-158.
PubMed

June 2017

HO G, Jonas BA, Li Q, Brunson A, et al
Early mortality and complications in hospitalized adult Californians with acute myeloid leukaemia.
Br J Haematol. 2017;177:791-799.
PubMed Abstract available

ONIDA F, de Wreede LC, van Biezen A, Eikema DJ, et al
Allogeneic stem cell transplantation in patients with atypical chronic myeloid leukaemia: a retrospective study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation.
Br J Haematol. 2017;177:759-765.
PubMed Abstract available

LIU CY, Hsieh FS, Chu PY, Tsai WC, et al
Carfilzomib induces leukaemia cell apoptosis via inhibiting ELK1/KIAA1524 (Elk-1/CIP2A) and activating PP2A not related to proteasome inhibition.
Br J Haematol. 2017;177:726-740.
PubMed Abstract available

KAYASTHA GK, Ranjitkar N, Gurung R, Kc RK, et al
The use of Imatinib resistance mutation analysis to direct therapy in Philadelphia chromosome/BCR-ABL1 positive chronic myeloid leukaemia patients failing Imatinib treatment, in Patan Hospital, Nepal.
Br J Haematol. 2017;177:1000-1007.
PubMed Abstract available

CORREA DE ARAUJO KOURY L, Ganser A, Berliner N, Rego EM, et al
Treating acute promyelocytic leukaemia in Latin America: lessons from the International Consortium on Acute Leukaemia experience.
Br J Haematol. 2017;177:979-983.
PubMed Abstract available

KAYASTHA GK, Ranjitkar N, Gurung R, Kc RK, et al
Treating Philadelphia chromosome/BCR-ABL1 positive patients with Glivec (Imatinib mesylate): 10 years' experience at Patan Hospital, Nepal.
Br J Haematol. 2017;177:991-999.
PubMed Abstract available

May 2017

TAO L, Clarke CA, Rosenberg AS, Advani RH, et al
Subsequent primary malignancies after diffuse large B-cell lymphoma in the modern treatment era.
Br J Haematol. 2017 May 25. doi: 10.1111/bjh.14638.
PubMed Abstract available

EPPERLA N, Pham AQ, Burnette BL, Wiseman GA, et al
Risk of histological transformation and therapy-related myelodysplasia/acute myeloid leukaemia in patients receiving radioimmunotherapy for follicular lymphoma.
Br J Haematol. 2017 May 3. doi: 10.1111/bjh.14688.
PubMed Abstract available

SCOTT S, Travis D, Whitby L, Bainbridge J, et al
Measurement of BCR-ABL1 by RT-qPCR in chronic myeloid leukaemia: findings from an International EQA Programme.
Br J Haematol. 2017;177:414-422.
PubMed Abstract available

RHEINGOLD SR, Tasian SK, Whitlock JA, Teachey DT, et al
A phase 1 trial of temsirolimus and intensive re-induction chemotherapy for 2nd or greater relapse of acute lymphoblastic leukaemia: a Children's Oncology Group study (ADVL1114).
Br J Haematol. 2017;177:467-474.
PubMed Abstract available

THOMPSON PA, Stingo F, Keating MJ, Wierda WG, et al
Long-term follow-up of patients receiving allogeneic stem cell transplant for chronic lymphocytic leukaemia: mixed T-cell chimerism is associated with high relapse risk and inferior survival.
Br J Haematol. 2017;177:567-577.
PubMed Abstract available

THOMPSON PA, Ravandi F
How I manage patients with hairy cell leukaemia.
Br J Haematol. 2017;177:543-556.
PubMed Abstract available

NIBLOCK A, McConville DO, Morrison PJ
Zygodactyly is strongly associated with Acute Myeloid Leukaemia.
Br J Haematol. 2017;177:659-660.
PubMed

EYRE TA, Fox CP, Shankara P, Went R, et al
Idelalisib-Rituximab induces clinical remissions in patients with TP53 disrupted B cell prolymphocytic leukaemia.
Br J Haematol. 2017;177:486-491.
PubMed

April 2017

MARTIN P, Chen Z, Cheson BD, Robinson KS, et al
Long-term outcomes, secondary malignancies and stem cell collection following bendamustine in patients with previously treated non-Hodgkin lymphoma.
Br J Haematol. 2017 Apr 17. doi: 10.1111/bjh.14667.
PubMed Abstract available

TOKUNAGA M, Yonekura K, Nakamura D, Haraguchi K, et al
Clinical significance of cutaneous adverse reaction to mogamulizumab in relapsed or refractory adult T-cell leukaemia-lymphoma.
Br J Haematol. 2017 Apr 3. doi: 10.1111/bjh.14634.
PubMed

BULDINI B, Rizzati F, Masetti R, Fagioli F, et al
Prognostic significance of flow-cytometry evaluation of minimal residual disease in children with acute myeloid leukaemia treated according to the AIEOP-AML 2002/01 study protocol.
Br J Haematol. 2017;177:116-126.
PubMed Abstract available

ORLOWSKI RJ, Porter DL, Frey NV
The promise of chimeric antigen receptor T cells (CARTs) in leukaemia.
Br J Haematol. 2017;177:13-26.
PubMed Abstract available

AKAHANE K, Li Z, Etchin J, Berezovskaya A, et al
Anti-leukaemic activity of the TYK2 selective inhibitor NDI-031301 in T-cell acute lymphoblastic leukaemia.
Br J Haematol. 2017;177:271-282.
PubMed Abstract available

CURTIS DJ
Targeted therapies for T-cell acute lymphoblastic leukaemia (T-ALL): what makes T-ALL TYK?
Br J Haematol. 2017;177:169-170.
PubMed

CHAN KL, Blombery P, Jones K, Lade S, et al
Plasmablastic Richter transformation as a resistance mechanism for chronic lymphocytic leukaemia treated with BCR signalling inhibitors.
Br J Haematol. 2017;177:324-328.
PubMed

FLEMING S, Ong DM, Jackson K, Avery S, et al
Partial response after induction chemotherapy has clinical relevance in acute myeloid leukaemia.
Br J Haematol. 2017;177:328-330.
PubMed

DELGADO J, Bielig T, Bonet L, Carnero-Montoro E, et al
Impact of the functional CD5 polymorphism A471V on the response of chronic lymphocytic leukaemia to conventional chemotherapy regimens.
Br J Haematol. 2017;177:147-150.
PubMed

March 2017

MINAMI M, Arita T, Iwasaki H, Muta T, et al
Comparative analysis of pulmonary hypertension in patients treated with imatinib, nilotinib and dasatinib.
Br J Haematol. 2017 Mar 24. doi: 10.1111/bjh.14608.
PubMed Abstract available

MARQUET J, Piris-Villaespesa M, Rodriguez E, Lopez S, et al
Skin lesions and cytological features in HTLV-1 associated adult T-cell leukaemia/lymphoma.
Br J Haematol. 2017 Mar 14. doi: 10.1111/bjh.14600.
PubMed

TASIAN SK, Hunger SP
Genomic characterization of paediatric acute lymphoblastic leukaemia: an opportunity for precision medicine therapeutics.
Br J Haematol. 2017;176:867-882.
PubMed Abstract available

CHETTY T, Masingi NI, Laher Z, Pretorius E, et al
Acute megakaryoblastic leukaemia: light microscopy and scanning electron microscopy of blast cells.
Br J Haematol. 2017;176:686.
PubMed

GROVE CS, Bolli N, Manes N, Varela I, et al
Rapid parallel acquisition of somatic mutations after NPM1 in acute myeloid leukaemia evolution.
Br J Haematol. 2017;176:825-829.
PubMed

QUINQUENEL A, Sicre de Fontbrune F, Durot E, Pannetier M, et al
Recovery of full donor chimerism with ibrutinib therapy in relapsed CLL after allogeneic stem cell transplantation.
Br J Haematol. 2017;176:997-999.
PubMed

TAM CS, Kimber T, Seymour JF
Ibrutinib monotherapy as effective treatment of central nervous system involvement by chronic lymphocytic leukaemia.
Br J Haematol. 2017;176:829-831.
PubMed

February 2017

SAWAS A, Farber CM, Schreeder MT, Khalil MY, et al
A phase 1/2 trial of ublituximab, a novel anti-CD20 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma or chronic lymphocytic leukaemia previously exposed to rituximab.
Br J Haematol. 2017 Feb 21. doi: 10.1111/bjh.14534.
PubMed Abstract available

SHARMAN JP, Farber CM, Mahadevan D, Schreeder MT, et al
Ublituximab (TG-1101), a novel glycoengineered anti-CD20 antibody, in combination with ibrutinib is safe and highly active in patients with relapsed and/or refractory chronic lymphocytic leukaemia: results of a phase 2 trial.
Br J Haematol. 2017;176:412-420.
PubMed Abstract available

RINGDEN O, Labopin M, Schmid C, Sadeghi B, et al
Sequential chemotherapy followed by reduced-intensity conditioning and allogeneic haematopoietic stem cell transplantation in adult patients with relapse or refractory acute myeloid leukaemia: a survey from the Acute Leukaemia Working Party of EBMT.
Br J Haematol. 2017;176:431-439.
PubMed Abstract available

WAN H, Cai J, Chen F, Zhu J, et al
SOX12: a novel potential target for acute myeloid leukaemia.
Br J Haematol. 2017;176:421-430.
PubMed Abstract available

BERTAINA A, Vinti L, Strocchio L, Gaspari S, et al
The combination of bortezomib with chemotherapy to treat relapsed/refractory acute lymphoblastic leukaemia of childhood.
Br J Haematol. 2017;176:629-636.
PubMed Abstract available

VARGHESE AM, Howard DR, Pocock C, Rawstron AC, et al
Eradication of minimal residual disease improves overall and progression-free survival in patients with chronic lymphocytic leukaemia, evidence from NCRN CLL207: a phase II trial assessing alemtuzumab consolidation.
Br J Haematol. 2017;176:573-582.
PubMed Abstract available

CHANG CK, Zhao YS, Xu F, Guo J, et al
TP53 mutations predict decitabine-induced complete responses in patients with myelodysplastic syndromes.
Br J Haematol. 2017;176:600-608.
PubMed Abstract available

ROBAK T, Hellmann A, Kloczko J, Loscertales J, et al
Randomized phase 2 study of otlertuzumab and bendamustine versus bendamustine in patients with relapsed chronic lymphocytic leukaemia.
Br J Haematol. 2017;176:618-628.
PubMed Abstract available

LUBBERT M, Ihorst G, Sander PN, Bogatyreva L, et al
Elevated fetal haemoglobin is a predictor of better outcome in MDS/AML patients receiving 5-aza-2'-deoxycytidine (Decitabine).
Br J Haematol. 2017;176:609-617.
PubMed Abstract available

GAYNON PS
"The Second Time is Sweeter After All".
Br J Haematol. 2017;176:511-512.
PubMed

BRANDER DM
Rationale for combinatory chronic lymphocytic leukaemia treatment paradigms in the era of the B-cell receptor pathway and anti-apoptotic inhibitors: how do we mix, match, and move forward?
Br J Haematol. 2017;176:337-340.
PubMed

GUPTA A, Das A, Naina HV
Cholecystitis as the initial presentation of acute myeloid leukaemia.
Br J Haematol. 2017;176:344.
PubMed

COELHO-SILVA JL, Carvalho LE, Oliveira MM, Franca-Neto PL, et al
Prognostic importance of CD56 expression in intermediate risk acute myeloid leukaemia.
Br J Haematol. 2017;176:498-501.
PubMed

BAI S, Hu S
BCR-ABL1-negative acute myeloid leukaemia relapsing as BCR-ABL1-positive disease.
Br J Haematol. 2017;176:514.
PubMed

January 2017

WANQUET A, Birsen R, Bonnet C, Boubaya M, et al
Management of central nervous system involvement in chronic lymphocytic leukaemia: a retrospective cohort of 30 patients.
Br J Haematol. 2017;176:37-49.
PubMed Abstract available

BROWN FC, Cifani P, Drill E, He J, et al
Genomics of primary chemoresistance and remission induction failure in paediatric and adult acute myeloid leukaemia.
Br J Haematol. 2017;176:86-91.
PubMed Abstract available

SEKIYA Y, Xu Y, Muramatsu H, Okuno Y, et al
Clinical utility of next-generation sequencing-based minimal residual disease in paediatric B-cell acute lymphoblastic leukaemia.
Br J Haematol. 2017;176:248-257.
PubMed Abstract available

ZEIDAN AM, Smith BD, Carraway HE, Gojo I, et al
A phase 2 trial of high dose lenalidomide in patients with relapsed/refractory higher-risk myelodysplastic syndromes and acute myeloid leukaemia with trilineage dysplasia.
Br J Haematol. 2017;176:241-247.
PubMed Abstract available

HASLE H, Kaspers GJ
Strategies for reducing the treatment-related physical burden of childhood acute myeloid leukaemia - a review.
Br J Haematol. 2017;176:168-178.
PubMed Abstract available

FRISHMAN-LEVY L, Izraeli S
Advances in understanding the pathogenesis of CNS acute lymphoblastic leukaemia and potential for therapy.
Br J Haematol. 2017;176:157-167.
PubMed Abstract available

MAGEE JA
Comment on: Genomics of primary chemoresistance and remission induction failure in paediatric and adult acute myeloid leukaemia.
Br J Haematol. 2017;176:5-6.
PubMed

PAN X, Nariai N, Fukuhara N, Saito S, et al
Monitoring of minimal residual disease in early T-cell precursor acute lymphoblastic leukaemia by next-generation sequencing.
Br J Haematol. 2017;176:318-321.
PubMed

September 2016

BIGENWALD C, Harel S, Chevignon F, Roos-Weil D, et al
Are myelodysplastic syndromes and acute myeloid leukaemia occurring during the course of lymphoma always therapy related?
Br J Haematol. 2016 Sep 23. doi: 10.1111/bjh.14323.
PubMed

BRAS AE, Beishuizen A, Langerak AW, Jongen-Lavrencic M, et al
CD38 expression in paediatric leukaemia and lymphoma: implications for antibody targeted therapy.
Br J Haematol. 2016 Sep 8. doi: 10.1111/bjh.14310.
PubMed

June 2016

GAYNON PS, Sun W
Oligoclonality and new agent evaluation in acute lymphoblastic leukaemia.
Br J Haematol. 2016;173:950-7.
PubMed Abstract available

WILLIAMS ME, Hong F, Gascoyne RD, Wagner LI, et al
Rituximab extended schedule or retreatment trial for low tumour burden non-follicular indolent B-cell non-Hodgkin lymphomas: Eastern Cooperative Oncology Group Protocol E4402.
Br J Haematol. 2016;173:867-75.
PubMed Abstract available

GIONA F, Moleti ML, De Benedittis D, Santopietro M, et al
Can chronic myeloid leukaemia in children and adolescents be successfully treated without haematopoietic stem cell transplant? A single centre experience.
Br J Haematol. 2016;173:749-53.
PubMed Abstract available

ZUNA J, Moericke A, Arens M, Koehler R, et al
Implications of delayed bone marrow aspirations at the end of treatment induction for risk stratification and outcome in children with acute lymphoblastic leukaemia.
Br J Haematol. 2016;173:742-8.
PubMed Abstract available

May 2016

TUCKER DL, Mihailescu L, Riordan R, Rule S, et al
Remineralization of lytic bone disease in a patient with small lymphocytic lymphoma using ibrutinib.
Br J Haematol. 2016 May 12. doi: 10.1111/bjh.14118.
PubMed

SOVERINI S, De Benedittis C, Mancini M, Martinelli G, et al
Present and future of molecular monitoring in chronic myeloid leukaemia.
Br J Haematol. 2016;173:337-49.
PubMed Abstract available

FERRET Y, Caillault A, Sebda S, Duez M, et al
Multi-loci diagnosis of acute lymphoblastic leukaemia with high-throughput sequencing and bioinformatics analysis.
Br J Haematol. 2016;173:413-20.
PubMed Abstract available

March 2016

TAKAHASHI H, Watanabe T, Kinoshita A, Yuza Y, et al
High event-free survival rate with minimum-dose-anthracycline treatment in childhood acute promyelocytic leukaemia: a nationwide prospective study by the Japanese Paediatric Leukaemia/Lymphoma Study Group.
Br J Haematol. 2016 Mar 31. doi: 10.1111/bjh.14068.
PubMed Abstract available

BURKHARDT B, Mueller S, Khanam T, Perkins SL, et al
Current status and future directions of T-lymphoblastic lymphoma in children and adolescents.
Br J Haematol. 2016 Mar 15. doi: 10.1111/bjh.14017.
PubMed Abstract available

MILES RR, Shah RK, Frazer JK
Molecular genetics of childhood, adolescent and young adult non-Hodgkin lymphoma.
Br J Haematol. 2016 Mar 11. doi: 10.1111/bjh.14011.
PubMed Abstract available

November 2015

GIBSON SE, Leeman-Neill RJ, Jain S, Piao W, et al
Proliferation centres of chronic lymphocytic leukaemia/small lymphocytic lymphoma have enhanced expression of MYC protein, which does not result from rearrangement or gain of the MYC gene.
Br J Haematol. 2015 Nov 16. doi: 10.1111/bjh.13844.
PubMed

Thank you for your interest in scientific medicine.

AMEDEO Leukemia is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: